
Novartis AG
NVSHealthcare|Drug Manufacturers - General|CH
$162.55
+0.62 (+0.38%)
DCF Value
$269.57
Graham Number
$48.20
Cash / Share
$4.75
Clinical Trials (527)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07488520 Integrating Point of Care Testing (POCT) For Newborn Screening and Early Care for Sickle Cell Disease in Yopougon, Côte d'Ivoire | Sickle Cell Disease (SCD) | P4 | Recruiting | 120 | Open-label | — |
| NCT05161195 Roll-over Study to Allow Continued Access to Ribociclib | Metastatic Breast Cancer | P4 | Active | 134 | Open-label | Ribociclib, Letrozole, Anastrozole, Goserelin, Tamoxifen, Fulvestrant |
| NCT06941792 Inclisiran Effectiveness in China: a Pragmatic Randomized Trial | Coronary Heart Disease | P4 | Active | 1,590 | RCT, Open-label | inclisiran sodium injection |
| NCT07489573 Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa | Hidradenitis Suppurativa (HS) | P4 | Recruiting | 36 | Open-label | Secukinumab |
| NCT07034690 Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in At-risk Adult Patients With Dyslipidemia | Atherosclerotic Cardiovascular Disease | P4 | Recruiting | 326 | RCT, Open-label | — |
| NCT04111978 MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO) | Ovarian Neoplasm Epithelial, Fallopian Tube Neoplasms | P3 | Recruiting | 540 | RCT, Double-blind | Letrozole 2.5mg |
| NCT05739383 A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. | Primary Prevention of Atherosclerotic Cardiovascular Disease | P3 | Active | 14,012 | RCT, Double-blind | Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, Placebo in 1.5ml |
| NCT07440290 DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. | Haematological Malignancy, Malignant Neoplasm | P2P3 | Recruiting | 30 | Open-label | Dabrafenib, Trametinib |
| NCT04765657 Study of Efficacy and Safety of Inclisiran in Asian Participants With Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD High Risk and Elevated Low Density Lipoprotein Cholesterol (LDL-C) | Hypercholesterolemia | P3 | Active | 345 | RCT, Double-blind | inclisiran sodium, Placebo |
| NCT07225504 A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis (SPMS) | P3 | Recruiting | 1,275 | RCT, Double-blind | Remibrutinib (blinded), Placebo, Remibrutinib (Open label) |
| NCT04573478 Atrasentan in Patients With IgA Nephropathy | IgA Nephropathy, Immunoglobulin A Nephropathy | P3 | Active | 404 | RCT, Double-blind | Atrasentan, Placebo, Zigakibart |
| NCT07498335 Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN | Berger Disease, Bergers Disease | P3 | Recruiting | 28 | Open-label | Drug: Atrasentan |
| NCT02925234 The Drug Rediscovery Protocol (DRUP Trial) | Cancer, Tumors | P2 | Recruiting | 1,550 | Open-label | Panitumumab, Olaparib, Dabrafenib, Nilotinib, Trametinib, Erlotinib, Trastuzumab and Pertuzumab (combination treatment), Vemurafenib and Cobimetinib (combination treatment), Vismodegib, Regorafenib, Nivolumab, Afatinib, Dabrafenib and trametinib, Ribociclib, Lenvatinib, Pembrolizumab, Durvalumab, Rucaparib, Axitinib, Palbociclib, Crizotinib, Sunitinib, Cabozantinib, Abemaciclib, Alectinib, Atezolizumab and Bevacizumab, Ipilimumab and nivolumab, Entrectinib, Talazoparib, Dacomitinib, Lorlatinib, Erdafitinib, Alpelisib, Niraparib, Pemigatinib, Selpercatinib, Tepotinib |
| NCT01872260 Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer | Breast Cancer | P1P2 | Active | 259 | RCT, Open-label | LEE011, Letrozole, BYL719 |
| NCT03206086 Eltrombopag for Fanconi Anemia | Fanconi Anemia | P2 | Active | 25 | Open-label | Eltrombopag |
| NCT05180695 HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas | Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma | P1P2 | Active | 47 | Open-label | Pazopanib, HDM201 |
| NCT06004661 Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | P2 | Active | 23 | Open-label | AAA617, 68Ga-PSMA-11 |
| NCT07048197 A Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Rheumatoid Arthritis and Sjogren's Disease | Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD) | P1P2 | Active | 27 | Open-label | Rapcabtagene autoleucel |
| NCT07549646 24VA021; VATCH Trametinib for Ras/MAPK Pathway VAs | Ras/MAPK Pathway Vascular Anomalies, Vascular Anomalies | P2 | Recruiting | 45 | Open-label | Trametinib |
| NCT03090165 Ribociclib and Bicalutamide in AR+ TNBC | Triple Negative Breast Cancer | P1P2 | Active | 37 | Open-label | ribociclib, ribociclib, Bicalutamide |
| NCT02881242 Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer | Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma | P2 | Active | 14 | Open-label | Trametinib |
| NCT04104776 A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas | Advanced Solid Tumor, Diffuse Large B Cell Lymphoma | P1P2 | Recruiting | 300 | Open-label | Tulmimetostat, Enzalutamide |
| NCT07431177 A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo | Non-segmental Vitiligo | P2 | Recruiting | 210 | RCT, Double-blind | GIA632, Placebo |
| NCT07226986 A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC | PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy | P1P2 | Recruiting | 123 | Open-label | AMO959, Enzalutamide, Abiraterone |
| NCT02858921 Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma | Melanoma | P2 | Active | 60 | RCT, Open-label | Dabrafenib, Trametinib, Pembrolizumab |
| NCT05750628 Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum Malaria | Uncomplicated Plasmodium Falciparum Malaria | P2 | Recruiting | 327 | RCT, Open-label | INE963, KAE609 (Cipargamin), SoC (Coartem), KLU156 |
| NCT07136428 Asciminib in HER2+ Breast Cancer Brain Metastases | HER2+ Metastatic Breast Cancer | P1P2 | Recruiting | 42 | Open-label | — |
| NCT03591510 A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML | FLT3-mutated Acute Myeloid Leukemia | P2 | Active | 22 | Open-label | Midostaurin, Fludarabine, Cytarabine, Daunorubicin or idarubicin, Mitoxantrone, Etoposide |
| NCT05445843 Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation. | Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation | P2 | Active | 95 | Open-label | JDQ443 |
| NCT05469360 Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants | Alzheimer Disease, Mild Cognitive Impairment | P1 | Active | 38 | RCT, Double-blind | NIO752, NIO752, Matching placebo, NIO752, NIO752, NIO752, Matching placebo |
| NCT06379217 NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer. | Metastatic Neuroendocrine Prostate Cancer | P1 | Active | 31 | Open-label | [68Ga]Ga-PSMA-11, [68Ga]GA-DOTA-TATE, [68Ga]Ga-NeoB, [177Lu]Lu-PSMA-617, [177Lu]Lu-DOTA-TATE, [177Lu]Lu-NeoB, L-Lysine HCl-L-Arginine HCl, 2.5 %,, Gonadotropin-releasing hormone (GnRH) analogues, GnRH antagonists, Antiemetics & antinauseants, Metoclopramide |
| NCT06155500 Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC) | Sickle Cell Disease | P1 | Active | 4 | Open-label | OTQ923 |
| NCT07340138 Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis | Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF) | P1 | Active | 3 | Open-label | Pelabresib, Ruxolitinib |
| NCT07443137 CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study) | Large-cell Lymphoma | P1 | Recruiting | 20 | Open-label | Rapcabtagene autoleucel (YTB323) |
| NCT07644364 HJB647 Phase 1b Study in Japanese Healthy Participants With Elevated Blood Pressure and Patients With Hypertension | Elevated Blood Pressure, Hypertension | P1 | Recruiting | 64 | RCT, Double-blind | HJB647, Placebo |
| NCT07422610 Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment | Advanced Malignancies and Hepatic Impairment | P1 | Recruiting | 24 | Open-label | pelabresib |
| NCT03349801 Development of Novel Clinical Endpoints in Intermediate AMD | Age Related Macular Degeneration (AMD) | Active | 718 | — | — | |
| NCT04671693 A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors. | Late Effects, Testicular Germ Cell Tumor Mixed | N/A | Active | 500 | Open-label | — |
| NCT04497285 Real World Study Using Comprehensive Genomic Data on the Next Treatment Decision Making in Metastatic Breast Cancer | Metastatic Breast Cancer | Active | 600 | — | — | |
| NCT05009160 DreaMS - Validation Study 1 | Multiple Sclerosis | Active | 300 | — | — | |
| NCT05017142 Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD) | Optic Neuritis, Transverse Myelitis | Recruiting | 500 | — | — | |
| NCT05918666 National Register of Actionable Mutations | Solid Tumours in Advanced Stages | Active | 2,098 | — | — | |
| NCT03577197 Southeast Netherlands Advanced Metastatic Breast Cancer Registry | Advanced Breast Cancer, Metastatic Breast Cancer | Recruiting | 7,000 | — | — | |
| NCT02622581 Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients | Metastatic Non-small Cell Lung Cancer (NSCLC), Non-small Cell Lung Cancer Metastatic | Recruiting | 14,500 | — | — | |
| NCT07779460 A Study Comparing Effectiveness of Kesimpta® (Ofatumumab) Versus Ocrevus® (Ocrelizumab) in Real-world Practice | Multiple Sclerosis | Recruiting | 7,466 | — | — | |
| NCT05344469 A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis | Relapsing Multiple Sclerosis | Recruiting | 800 | — | — | |
| NCT07378969 A Non-Interventional Study PASS to Characterize Secondary Malignancies of Tcell Origin Following Tisagenlecleucel Therapy | Secondary Malignancies of T-cell Origin | Recruiting | 30 | — | — | |
| NCT07543419 Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe HS Within the Italian Population | Hidradenitis Suppurativa | Recruiting | 250 | — | — | |
| NCT04666272 Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection | Melanoma | Active | 78 | — | dabrafenib, trametinib | |
| NCT07758270 Brain Imaging and Immune Changes During Remibrutinib Treatment in Multiple Sclerosis. | Multiple Sclerosis (MS) - Relapsing-remitting | Recruiting | 15 | — | Remibrutinib, Ocrelizumab (US) | |
| NCT06770543 Leqvio rPMS (Regulatory Post-Marketing Surveillance in Korea) | Primary Hypercholesterolemia or Mixed Dyslipidemia | Recruiting | 1,500 | — | — | |
| NCT06643936 E3 Diabetes - Closing the Gap in Diabetes Control | Type 2 Diabetes | N/A | Active | 150 | RCT, Double-blind | — |
| NCT07549516 A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in Germany | Leukemia, Chronic Myeloid | Recruiting | 380 | — | — | |
| NCT07594587 A Study of Ruxolitinib in Patients With Graft-Versus Host Disease | Graft-Versus-Host Disease | Recruiting | 395 | — | — | |
| NCT07465666 A Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab Emirates | Hypertension | Recruiting | 500 | — | — | |
| NCT03958136 Clinico-biological Data Collection Study of Metastatic Breast Cancer | Breast Cancer | N/A | Active | 289 | Open-label | Biomarkers blood, urine and microbiota samples |
| NCT06287268 Revolade Tablets Specified Drug-use Survey | Aplastic Anemia | Recruiting | 10 | — | — | |
| NCT06785779 Short-term Treatment Satisfaction in Hidradenitis Suppurativa Patients Initiated on Cosentyx in Routine Clinical Practice in Saudi Arabia | Hidradenitis Suppurativa (HS) | Recruiting | 77 | — | — | |
| NCT01521715 First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma | Locally Advanced and/or Metastatic Renal Cell Carcinoma, Carcinoma, Renal Cell | P4 | Completed | 44 | Open-label | Pazopanib |
| NCT01266837 Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2) | Metastatic Renal Cell Carcinoma, Failure of Exactly One Prior VEGF-targeted Therapy | P4 | Completed | 64 | Open-label | Everolimus |
| NCT02248571 Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab | Breast Cancer Recurrent, HER2/Neu-negative Carcinoma of Breast | P4 | Completed | 85 | RCT, Open-label | Bevacizumab, Capecitabine, Everolimus, Exemestane |
| NCT00170859 Everolimus Versus Mycophenolate Mofetil in Combination With Reduced Dose Cyclosporine Microemulsion in Maintenance Heart Transplant Recipients | Heart Transplantation | P4 | Completed | — | RCT, Open-label | Everolimus |
| NCT00332462 A Study to Evaluate the Efficiency of Intravenously Administered Cyclosporine in de Novo Liver Transplant Recipients | Liver Transplantation | P4 | Completed | 34 | Open-label | Cyclosporine (Sandimmun® i.v.), Cyclosporine (Sandimmun® Optoral) |
| NCT01206088 Tasigna in Glivec-resistant or Intolerant Patients in CML | CML, Nilotinib | P4 | Completed | 93 | Open-label | nilotinib |
| NCT00760266 Blood Pressure Lowering of Aliskiren HCTZ Compared to HCTZ in Stage 2 Systolic Hypertension in Older Population | Hypertension | P4 | Completed | 451 | RCT, Double-blind | Aliskiren, Hydrochlorothiazide |
| NCT01935128 Evaluation of Calcineurin-inhibitor Reduction With Conversion at 2 Months to Everolimus/Reduced Tacrolimus in Renal Transplant Recipients Following Campath® Induction | Renal Transplant | P4 | Completed | 55 | Open-label | Arm 1 Everolimus/Reduced dose tacrolimus |
| NCT01518101 Vildagliptin Versus Liraglutide - Patient Preference After Receiving Both Medications | Type 2 Diabetes | P4 | Completed | 62 | RCT, Open-label | Vildagliptin/ Metformin, Liraglutide, Metformin |
| NCT01464229 Iloperidone Augmentation of SSRIs for Patients With Major Depressive Disorder With Residual Anger and Irritability | Major Depressive Disorder | P4 | Completed | 20 | RCT, Double-blind | Iloperidone, Placebo |
| NCT00691873 Study to Evaluate the Effect of Xolair(Omalizumab) on Improving the Tolerability of Specific Immunotherapy in Patients With at Least Moderate Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids | Asthma | P4 | Completed | 14 | RCT, Double-blind | Placebo, Xolair |
| NCT02069886 Effect of Deferasirox on Endocrine Complications in Subjects With Transfusion Dependent Thalassemia | Thalassemia (Transfusion Delendent) | P4 | Withdrawn | — | Open-label | deferasirox |
| NCT00660309 A Clinical Study to Evaluate Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus | Type 2 Diabetes Mellitus | P4 | Completed | 45 | RCT, Open-label | Aliskiren, Irbesartan, Captopril |
| NCT00776009 Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting. | Attention-Deficit/Hyperactivity Disorder (ADHD) | P4 | Completed | 165 | RCT, Double-blind | Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR), Placebo |
| NCT00965094 Efficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant Recipients | Chronic Renal Failure | P4 | Completed | 36 | RCT, Open-label | Everolimus, Tacrolimus (FK506), Basiliximab, Enteric Coated Mycophenolate Sodium (EC-MPS), Corticosteroids |
| NCT00238966 Extension Study to Assess Tolerability and Safety of Enteric-coated Mycophenolate Sodium in Renal Transplant Recipients Who Received Mycophenolate Mofetil | Renal Transplantation | P4 | Completed | 187 | Open-label | Enteric-Coated Mycophenolate Sodium (EC-MPS) |
| NCT01056822 Multicenter, Randomized, Open-label Study to Assess Whether Treatment With Mycophenolate Sodium (MPS) Allows Higher Dose Optimization Versus Mycophenolate Mofetil (MMF) Leading to a Dose Reduction of Tacrolimus. Maximiza Study. | Prophilaxis of Acute Rejection in Patients Receiving a Renal Allograft | P4 | Completed | 89 | RCT, Open-label | 1, 2 |
| NCT00738257 A Prospective, Multicentre, Open-label Randomised Controlled Study to Investigate the Effectiveness of Pamidronate in the Prevention of Bone Loss in de Novo Renal Transplant Patients. | Bone Loss | P4 | Completed | 126 | RCT, Open-label | Pamidronate |
| NCT02976194 Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy | Exudative Age-related Macular Degeneration, Polypoidal Choroidal Vasculopathy | P4 | Unknown | 28 | Open-label | ranibizumab |
| NCT00942994 Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic Hypertension | Hypertension | P4 | Completed | 412 | RCT, Double-blind | Aliskiren/Amlodipine, Aliskiren/Amlodipine and Hydrochlorothiazide (HCTZ) |
| NCT01211327 Topical Cyclosporine for Vernal Keratoconjunctivitis (VKC) in Rwanda | Vernal Keratoconjunctivitis | P4 | Completed | 366 | RCT, Double-blind | Cyclosporine A, Dexamethasone |
| NCT01490840 Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis | Fatigue in Multiple Sclerosis | P4 | Terminated | 178 | Open-label | — |
| NCT00772577 Study of the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI ≥ 30) With Stage 2 Hypertension | Hypertension | P4 | Completed | 386 | RCT, Double-blind | Aliskiren Hydrochlorothiazide, Ramipril |
| NCT00302705 Comparison of the Antihypertensive Efficacy of Valsartan and Enalapril After Missing One Dose | Hypertension | P4 | Completed | 150 | RCT, Open-label | Valsartan, Enalapril |
| NCT00845871 Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food | Transfusional Hemosiderosis | P4 | Completed | 65 | Open-label | deferasirox: |
| NCT02779257 Pasireotide Treatment for Neuroendocrine Tumor | Gastro-enteropancreatic Neuroendocrine Tumor | P4 | Withdrawn | — | Open-label | Pasireotide, Diazoxide |
| NCT00154297 Efficacy and Safety of Early Versus Delayed Administration of Everolimus in de Novo Renal Transplant Patients | Renal Transplantation | P4 | Completed | 139 | RCT, Open-label | Everolimus (RAD001) |
| NCT00171574 Antiproteinuric Effect of Valsartan and Lisinopril | Hypertension, Diabetic Nephropathy | P4 | Completed | 124 | RCT, Double-blind | Valsartan, Valsartan plus HCTZ, Lisinopril |
| NCT01169701 24 Months Follow-up, Two Arm Study to Compare the Cardiovascular Profile in a Regimen With Everolimus + Mycophenolic Acid (MPA) Versus (vs.) a Regimen of CNI+MPA in Maintenance Renal Transplant Recipients | Renal Transplant | P4 | Completed | 71 | RCT, Open-label | Everolimus, Tacrolimus, Mycophenolic acid (MPA) |
| NCT01666197 Efficacy and Safety of Diclofenac Potassium 25 mg Tablet Taken Three Times Daily in Subjects With Acute Joint Pain | Ankle Sprain | P4 | Completed | 100 | RCT, Double-blind | diclofenac potassium 25 mg tablet, placebo |
| NCT00948766 Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44 | Alzheimer's Disease | P4 | Completed | 716 | RCT, Double-blind | Rivastigmine 4.6 mg/24 h (5 cm^2), Rivastigmine 9.5 mg/24 h (10 cm^2), Rivastigmine 13.3 mg/24 h (15 cm^2), Placebo |
| NCT00241046 Letrozole in the Treatment of 1st and 2nd Line Hormone Receptor Positive Breast Cancer: Pre-therapeutic Risk Assessment | Metastatic Breast Cancer | P4 | Terminated | 13 | Open-label | Letrozole |
| NCT00909324 Efficacy, Tolerability, and Comfort of 0.3% Hypromellose Eyedrops in Patients Undergoing LASIK Surgery | Dry Eye | P4 | Completed | 170 | RCT, Open-label | Pre-LASIK 0.3% hypromellose, Post-LASIK 0.3% hypromellose |
| NCT02123108 Safety and Efficacy of Basiliximab, Delayed Dose Tacrolimus Plus ECMPA (Enteric Coated Mycophenolic Acid) Following Liver Transplantation | Liver Transplantation | P4 | Completed | 59 | RCT, Open-label | Basiliximab, Tacrolimus, Tacrolimus, Mycophenolic Acid |
| NCT00439738 Safety/Efficacy of Valsartan/Hydrochlorothiazide Combination Compared to Hydrochlorothiazide in Obese Hypertensive Adults | Hypertension | P4 | Completed | 412 | RCT, Double-blind | HCTZ + Amlodipine, Valsartan/HCTZ |
| NCT00241085 Effect of Valsartan on Proteinuria in Patients With Hypertension and Diabetes Mellitus | PROTEINURIA, Hypertension | P4 | Completed | 392 | RCT, Double-blind | valsartan |
| NCT00115115 Donor Dopamine and Initial Graft Function | Kidney Transplantation, ESRD | P4 | Completed | 487 | RCT, Open-label | Dopamine infusion to brain dead organ donors |
| NCT02254668 Intracoronary Analysis of Cardiac Allograft Vasculopathy by Means of Optical Coherence Tomography | Intimal Proliferation, Immunosuppression | P4 | Unknown | 278 | RCT, Open-label | — |
| NCT00673218 The Effect of Xolair on Inhibiting Leukotriene and Cytokine (IL-4 and IL-13) Release From Blood Basophils | Allergy | P4 | Unknown | 25 | RCT, Double-blind | Placebo, Xolair |
| NCT00280540 Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension | Hypertension | P4 | Completed | 648 | RCT, Double-blind | Valsartan/Hydrochlorothiazide |
| NCT00639691 A Compassionate Access Protocol to Assess the Safety of XolairTM (Omalizumab) in Patients (≥ 6 Years Old) With Severe Allergic Asthma Who Remain Symptomatic Despite Optimal Therapy | Asthma | P4 | Completed | 48 | Open-label | omalizumab |
| NCT02366468 Study of Efficacy of Ranibizumab in Different Regimens in Patients With Diabetic Macula Edema | Diabetic Retinopathy | P4 | Completed | 135 | RCT, Single-blind | ranibizumab 0.5 mg |
| NCT01529619 Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors | Alzheimer's Disease | P4 | Completed | 52 | Open-label | Rivastigmine transdermal patch |
| NCT01578330 A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720 | Multiple Sclerosis, Relapsing-Remitting | P4 | Completed | 42 | Open-label | Fingolimod |
| NCT04774926 Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab. | Neovascular Age-related Macular Degeneration | P4 | Completed | 122 | Open-label | Brolucizumab |
| NCT01218035 Efficacy of Zoledronic Acid in Enhancement of Early Stability of Cementless Primary Hip Prosthesis | Hip Osteoarthritis | P4 | Completed | 49 | RCT, Double-blind | zoledronic acid |
| NCT02546674 Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline. | Chronic Myeloid Leukemia | P4 | Completed | 171 | Open-label | Nilotinib |
| NCT05080218 COVID-19 VaccinE Response in Rheumatology Patients | Rheumatoid Arthritis, Psoriatic Arthritis | P4 | Completed | 841 | RCT, Open-label | Upadacitinib, Abatacept, Secukinumab, Tofacitinib, TNF Inhibitor, Canakinumab Injection, Baricitinib, Ixekizumab |
| NCT01043874 Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response | Philadelphia Chromosome Positive, Chronic Myelogenous Leukemia in Chronic Phase | P4 | Completed | 45 | Open-label | Nilotinib |
| NCT00658333 A Study Designed to Compare the Tolerability of an Increased Dose of Enteric-coated Mycophenolate Acid (MPA) in Renal Transplant Patients Whose Dose of Mycophenolate Mofetil (MMF) Was Reduced Due to Gastrointestinal Symptoms | Renal Transplantation | P4 | Terminated | 30 | RCT, Double-blind | Enteric-coated Mycophenolate Acid (EC-MPA), Mycophenolate Mofetil (MMF), Placebo MMF, Placebo EC-MPA |
| NCT01541189 Double-dose Valsartan Monotherapy in Hypertension Treatment: an Effectiveness and Safety Evaluation in Chinese Patients. | Hypertension | P4 | Completed | 200 | Open-label | Valsartan |
| NCT02842749 Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China | Pancreatic Neuroendocrine Tumors | P4 | Completed | 61 | Open-label | everolimus |
| NCT00749515 Pilot Study for Patients With Poor Response to Deferasirox | Transfusion-dependent Hemachromatosis, Thalassemia Major | P4 | Completed | 15 | Open-label | Deferoxamine, Deferasirox |
| NCT02178540 Study to Validate the Instructions for Use of TOBI® Podhaler™ in Cystic Fibrosis Patients | Cystic Fibrosis | P4 | Completed | 45 | Open-label | Placebo |
| NCT01196546 Efficacy and Safety of Combination Therapy of Vildagliptin/Metformin in Patients in Type 2 Diabetes Mellitus (T2DM) | Type 2 Diabetes Mellitus | P4 | Completed | 161 | Open-label | vildagliptin/metformin |
| NCT00509990 Open Label Study of Long Term Treatment of Pediatric Treatment of Atopic Dermatitis With Pimecrolimus Cream 1% Within a Usual Clinical Setting | Atopic Dermatitis | P4 | Completed | 200 | Open-label | Pimecrolimus |
| NCT00035997 Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis | Prostate Cancer | P4 | Completed | 261 | Open-label | Zometa |
| NCT01106482 An Extension Study to Determine the Persistence of Tick-borne Encephalitis (TBE)-Specific Antibody Responses Among Children and Adolescents Previously Immunized Against TBE | Tick Borne Encephalitis (TBE) | P4 | Completed | 126 | RCT, Open-label | — |
| NCT00150059 Efficacy and Safety of Pimecrolimus Cream 1% in Patients ≥ 3 Months of Age With Mild or Moderate Atopic Dermatitis | Atopic Dermatitis | P4 | Completed | — | Open-label | Pimecrolimus Cream 1% |
| NCT02344472 Detect V / CHEVENDO (Chemo vs. Endo) | Metastatic Breast Cancer | P3 | Unknown | 271 | RCT, Open-label | pertuzumab, Trastuzumab, Capecitabine, Paclitaxel, Vinorelbine, Docetaxel, Exemestane, Letrozole, Anastrozole, Fulvestrant, Ribociclib, nab-Paclitaxel, eribulin, leuprorelin, goserelin |
| NCT04828161 A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19 | COVID-19 | P2P3 | Terminated | 407 | RCT, Double-blind | ensovibep, Placebo |
| NCT00433589 Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes | Breast Cancer | P3 | Completed | 6,600 | RCT, Open-label | anthracycline-based, docetaxel and capecitabine, tamoxifen, Letrozole |
| NCT00219739 STI571 ProspectIve RandomIzed Trial: SPIRIT | Chronic Myeloid Leukemia | P3 | Completed | 789 | RCT, Open-label | Imatinib mesylate 400 mg, Imatinib mesylate 600 mg, Imatinib 400 mg + Peg-Interferon, Imatinib mesylate 400 mg + Cytarabine |
| NCT01028092 mTor-inhibitor (EVERolimus) Based Immunosuppressive Strategies for CNI Minimisation in OLD for Old Renal Transplantation | Renal Transplant | P3 | Completed | 327 | RCT, Open-label | Anti R-IL2 + Cyclosporine, Thymoglobulin + Everolimus, Anti R-IL2 + Cyclosporine then Everolimus |
| NCT01803763 Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients | Chronic Urticaria, Chronic Idiopathic Urticaria | P2P3 | Completed | 30 | RCT, Double-blind | Omalizumab (Xolair), Placebo |
| NCT03462251 Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line | Breast Cancer, Hormone Receptor Positive Tumor | P3 | Completed | 41 | RCT, Open-label | — |
| NCT01110889 Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder | Major Depressive Disorder | P3 | Completed | 582 | RCT, Double-blind | Agomelatine (AGO178C), Agomelatine (AGO178C), Placebo |
| NCT00344110 Study Comparing SPP100 (Aliskiren) 150mg to Placebo and to Losartan 50mg in Patients With Mild to Moderate Essential Hypertension | Hypertension | P3 | Completed | 768 | RCT, Double-blind | Aliskiren |
| NCT00735410 Safety and Immunogenicity of Trivalent Split Influenza Vaccine Using the Strain Composition 2008/2009 | Seasonal Influenza, Vaccine | P3 | Completed | 134 | RCT, Open-label | Seasonal Influenza Vaccine |
| NCT03917459 COmparing arNi and Ace For Improving Erectile Dysfunction in mEN With reduCed Ejection Fraction Heart Failure | Heart Failure, Heart Failure, Systolic | P3 | Completed | 27 | RCT, Double-blind | LCZ696, Enalapril matching placebo, Enalapril, LCZ696 matching placebo |
| NCT03386474 Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD | Neovascular Age-related Macular Degeneration | P3 | Completed | 151 | Double-blind | Brolucizumab 6 mg, Aflibercept 2 mg |
| NCT00098046 Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infection | Chickenpox, Herpes Zoster | P3 | Completed | 76 | Open-label | famciclovir |
| NCT01586962 Warming Sensation Intensity and Acceptability of the Flavour, Local Tolerability of Paracetamol 500 mg + Pseudoephedrine 30 mg Syrup in Patients Suffering a URTI | Upper Respiratory Infections | P3 | Completed | 56 | Open-label | IFF flavor 316 282, Paracetamol, Pseudoephedrine |
| NCT01764841 Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE) | Bronchiectasis | P3 | Completed | 416 | RCT, Double-blind | Ciprofloxacin DPI (BAYQ3939), Placebo |
| NCT01257451 Safety and Efficacy of Galvus in Elderly Type 2 Diabetes Patients | Type 2 Diabetes Mellitus | P3 | Completed | 431 | RCT, Double-blind | Vildagliptin, Placebo |
| NCT01617681 Efficacy, Safety and Tolerability of Multiple Doses of Valsartan in Children With Hypertension With or Without CKD | Pediatric Hypertension With or Without CKD | P3 | Completed | 127 | RCT, Double-blind | VAL489, VAL489 matching placebo |
| NCT05350072 Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome | Sjogren Syndrome | P3 | Completed | 275 | RCT, Double-blind | VAY736 |
| NCT04206761 Investigating the Effects of QVM149 on MRI Ventilation Defects | Asthma | P3 | Withdrawn | — | RCT, Open-label | QVM149, High Dose Dual Therapy (ICS/LABA) |
| NCT00005073 Zoledronate Plus Standard Therapy Compared With Placebo Plus Standard Therapy to Prevent Bone Metastases in Patients With Recurrent Prostate Cancer That Has No Symptoms | Prostate Cancer | P3 | Terminated | 544 | RCT | zoledronic acid |
| NCT00529451 Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg in Patients With Essential Hypertension Compared to Ramipril 5 mg | Hypertension | P3 | Completed | 1,613 | RCT, Double-blind | Aliskiren, Ramipril |
| NCT00995709 Phase III Study in Refractory Behcet's Disease | Behcet Disease | P3 | Completed | 118 | RCT, Double-blind | AIN457, AIN457, Placebo |
| NCT01529632 Comparison of Safety and Efficacy of the Combination Product QVA149A Against the Concurrent Administration of the Individual Components, QAB149 and NVA237, in Patients With Chronic Obstructive Pulmonary Disease (COPD) | Chronic Obstructive Pulmonary Disease | P3 | Completed | 193 | RCT, Double-blind | QVA149, NVA237, QAB149, Placebo |
| NCT00134953 Efficacy and Safety of Rivastigmine in Patients With Mild Cognitive Impairment | Cognitive Symptoms | P3 | Terminated | 24 | RCT, Double-blind | Rivastigmine |
| NCT03785405 Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF | Heart Failure | P3 | Completed | 216 | Open-label | sacubitril/valsartan |
| NCT00329940 Safety and Rheumatologic Tolerability of Letrozole in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer | Breast Cancer | P3 | Completed | 200 | Open-label | Letrozole |
| NCT01103024 Extension Study to Assess Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis | Uveitis | P3 | Withdrawn | — | RCT, Double-blind | AIN457, AIN457, AIN457, Placebo |
| NCT02091908 Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Underlying Medical Conditions | Influenza, Human | P3 | Completed | 540 | RCT, Double-blind | Novartis Investigational H5N1 vaccine, Novartis Investigational H5N1 vaccine, Novartis Seasonal Influenza Vaccine, Novartis Seasonal Influenza Vaccine |
| NCT00644059 Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subjects (Aged 6 to <72 Months) Versus Control Vaccines | Influenza, Human | P3 | Completed | 4,902 | RCT, Single-blind | Adjuvanted trivalent inactivated subunit influenza vaccine, Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine, Meningococcal C conjugate vaccine or tick-borne encephalitis vaccine |
| NCT00365820 Efficacy and Safety of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain | Constipation | P2P3 | Terminated | 670 | RCT, Double-blind | Tegaserod |
| NCT02962388 The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line | Essential Thrombocythemia | P2P3 | Terminated | 13 | RCT, Open-label | Anagrelide, Ruxolitinib (JAKAVI®), IFNα/ PegIFNα |
| NCT04935359 Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2 | Metastatic Pancreatic Ductal Adenocarcinoma | P3 | Completed | 511 | RCT, Double-blind | NIS793, Nab-paclitaxel, Gemcitabine, Placebo |
| NCT00396656 Safety and Efficacy of Valsartan vs Atenolol and Hydrochlorothiazide Combination on Blood Flow in Hypertensive Patients | Hypertension | P3 | Completed | 30 | RCT, Open-label | Atenolol, Hydrochlorothiazide (HCTZ)), Valsartan |
| NCT02474069 Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis | Moderate to Severe Plaque-type Psoriasis | P3 | Completed | 772 | RCT, Double-blind | Secukinumab |
| NCT02720536 Extended Evaluation of Deferasirox Film-coated Tablet (FCT) Formulation | Chronic Iron Overload | P3 | Completed | 53 | Open-label | Deferasirox |
| NCT01828112 LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib | Non-Small Cell Lung Cancer | P3 | Completed | 231 | RCT, Open-label | Ceritinib, Pemetrexed, Docetaxel |
| NCT01762761 Eltrombopag Phase III Study In Chinese Chronic ITP Patients | Purpura, Thrombocytopenic, Idiopathic and Hepatitis C | P3 | Completed | 155 | RCT, Double-blind | eltrombopag, placebo |
| NCT00945841 Safety and Immunogenicity, Inactivated Split Influenza Vaccine, Using the Strain Composition 2009/2010 | Seasonal Influenza | P3 | Completed | 126 | RCT, Open-label | inactivated split influenza vaccine |
| NCT03158311 Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + Tiotropium | Asthma | P3 | Completed | 1,426 | RCT, Single-blind | QVM149, Salmeterol/fluticasone plus tiotropium |
| NCT02571777 Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma | Asthma | P3 | Completed | 3,092 | RCT, Double-blind | QVM149 150/50/160, QVM149 150/50/80, QMF149 150/320, QMF149 150/160, salmeterol/fluticasone |
| NCT00130351 A 3-week Study Investigating Patient Use and Functionality of Formoterol in a Novel Inhalation Device in Patients With Asthma | Asthma | P3 | Completed | 155 | Open-label | — |
| NCT01448057 Evaluation of Efficacy and Safety of Tablets of Paracetamol, Dimethindene Maleate and Phenylephrine Hydrochloride in Reducing Symptoms of Common Cold and Flu | Upper Respiratory Tract Infection, Nasal Congestion | P3 | Completed | 341 | RCT, Single-blind | Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets, Paracetamol (500 mg) tablets |
| NCT00802841 Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib | Chronic Myelogenous Leukemia | P3 | Completed | 191 | RCT, Open-label | nilotinib, imatinib |
| NCT02292446 Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available. | Polycythemia Vera | P3 | Completed | 161 | Open-label | Ruxolitinib |
| NCT02116803 An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective | Solid Tumors | P2P3 | Completed | 12 | Open-label | dovitinib, fulvestrant |
| NCT00514488 Imatinib Standard Dose (400 mg/Day) Versus Imatinib High Dose (800 mg/Day) | Chronic Myeloid Leukemia | P3 | Completed | — | RCT, Open-label | STI571 (400 mg/day; or 800 mg/day) |
| NCT03626545 Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy | Non-Small-Cell Lung | P3 | Terminated | 245 | RCT, Double-blind | Canakinumab, Docetaxel |
| NCT03217422 ADCC Mediated B-Cell dEpletion and BAFF-R Blockade | Autoimmune Hepatitis | P2P3 | Completed | 68 | RCT, Double-blind | VAY736 |
| NCT01574651 The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD) | Chronic Obstructive Pulmonary Disease (COPD) | P3 | Completed | 934 | RCT, Double-blind | QVA149, Placebo to tiotropium, Placebo to formoterol, Tiotropium, Formoterol, Placebo to QVA149 |
| NCT00531440 This is a 2-year Follow-up Study to Evaluate the Long-term Effects in Patients Who Completed the Study CRAD001A2307. | Renal Transplantation | P3 | Completed | 256 | RCT, Open-label | Everolimus (RAD001) |
| NCT01840410 Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization. | Choroidal Neovascularization (CNV) | P3 | Completed | 183 | RCT, Double-blind | Ranibizumab |
| NCT01743989 A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML. | Philadelphia Chromosome Positive (PH+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) | P3 | Completed | 620 | RCT, Open-label | Nilotinib |
| NCT03259074 Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar) | Ankylosing Spondylitis | P3 | Completed | 859 | RCT, Single-blind | Placebo, GP2017 (adalimumab biosimilar), AIN457 150 mg |
| NCT01593527 Canakinumab in the Treatment of Gouty Arthritis Flare(s) and Prevention of New Flares in Patients With Chronic Kidney Disease | Acute Gouty Arthritis | P3 | Withdrawn | — | RCT, Double-blind | ACZ885, Triamcinelone acetonide |
| NCT00308425 Safety and Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) Plus Valsartan in Patients With Kidney Transplants (MYTHOS | De Novo Renal Transplantation | P3 | Completed | 119 | RCT, Open-label | Enteric-coated Mycophenolate sodium (EC-MPS), valsartan |
| NCT00376259 Study of Combination Therapy With LdT Plus Adefovir Versus Adefovir Alone | Hepatitis B | P3 | Terminated | 43 | RCT, Open-label | telbivudine, adefovir dipivoxil |
| NCT01160211 A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer | Neoplasms, Breast | P3 | Completed | 369 | RCT, Open-label | Lapatinib, Trastuzumab, Aromatase Inhibitor, Lapatinib |
| NCT00262990 Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer | Ovarian Cancer, Fallopian Tube Cancer | P3 | Completed | 829 | RCT, Open-label | EPO906 (Patupilone), doxorubicin |
| NCT00320710 Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer | Breast Cancer | P3 | Completed | 416 | RCT, Double-blind | Zoledronic acid, Placebo |
| NCT00330317 Safety and Efficacy of Hormone Therapy With Letrozole in Postmenopausal Women With Breast Cancer | Breast Cancer | P3 | Completed | 300 | Open-label | letrozole |
| NCT01410474 Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 18 Years in Taiwan | Bacterial Meningitis | P3 | Completed | 341 | Open-label | Meningococcal ACWY conjugate vaccine |
| NCT01232478 I Change Adherence & Raise Expectations | Cystic Fibrosis | P3 | Completed | 641 | RCT, Open-label | — |
| NCT04156620 Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpA | Ankylosing Spondylitis | P3 | Completed | 527 | RCT, Double-blind | Secukinumab, Placebo |
| NCT00241007 A Study Comparing Valsartan With And Without Hydrochlorothiazide In Patients With Hypertension | Hypertension | P3 | Completed | 836 | RCT, Double-blind | VALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE |
| NCT01727141 A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation. | Chronic Obstructive Pulmonary Disease (COPD) | P3 | Completed | 1,042 | RCT, Double-blind | QVA149, QAB149, NVA237, Placebo |
| NCT00529529 Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma | Asthma | P3 | Completed | 805 | RCT, Double-blind | Indacaterol 300 μg, Salmeterol 50 μg, Placebo to indacaterol, Placebo to salmeterol |
| NCT00232102 Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia | Dyspepsia | P3 | Completed | 423 | Open-label | Tegaserod |
| NCT00667719 A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension | Essential Hypertension | P3 | Completed | 564 | Open-label | Aliskiren, Amlodipine, Hydrochlorothiazide |
| NCT00151671 Effect of a Perioperative Oral Nutritional Supplementation on Patients Undergoing Hepatic Surgery for Liver Cancer | Liver Cancer, Hepatocellular Carcinoma | P2P3 | Terminated | 35 | RCT, Double-blind | Oral Impact®, Placebo |
| NCT01996319 Randomized, Double-blind, Placebo-controlled, Multicenter, Cross-over Study to Assess the Effects of a 3 Week Therapy Each With QVA149 Versus Placebo on Pulmonary Function and Average Physical Activity Levels in Patients With COPD. | Chronic Obstructive Pulmonary Disease | P3 | Completed | 194 | RCT, Double-blind | QVA149, Placebo |
| NCT00120536 Efficacy and Safety of Three Doses of Vildagliptin in Drug Naive Patients With Type 2 Diabetes | Diabetes Mellitus, Type 2 | P3 | Completed | 288 | RCT, Double-blind | vildagliptin |
| NCT00519064 Immunogenicity and Safety of an Adjuvanted Inactivated Subunit Influenza Vaccine to Those of a Non-adjuvanted Inactivated Subunit Influenza Vaccine, When Administered to Adults Affected by Chronic Diseases | Influenza Disease | P3 | Completed | 361 | RCT, Single-blind | Adjuvanted influenza vaccine |
| NCT00136799 Efficacy and Safety of Fluvastatin in Different Doses in Adults With Mixed Dyslipidemia or Primary Hypercholesterolemia | Mixed Dyslipidemia, Hypercholesterolemia | P3 | Completed | 325 | RCT, Double-blind | Fluvastatin |
| NCT00579345 Second Extension Study to Evaluate Safety and Tolerability of Influenza Vaccines in Adults and Elderly, and to Evaluate Immunogenicity and Concomitant Vaccination With Pneumococcal Vaccine in a Subgroup | Influenza | P3 | Completed | 1,522 | RCT, Single-blind | Cell culture derived seasonal trivalent influenza vaccine (cTIV), Influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a)., cTIV or eTIV_a, cTIV+PV OR eTIV_a+PV |
| NCT01202903 Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy | Persistent Allergic Asthma | P3 | Completed | 616 | RCT, Double-blind | Omalizumab, Placebo |
| NCT01964989 Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children. | Influenza Virus | P3 | Completed | 10,644 | RCT, Double-blind | Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV), Non-adjuvanted Trivalent Influenza Vaccine (TIV) / Quadrivalent Influenza Vaccine (QIV) |
| NCT04838613 Study of Diagnostic Performance of [18F]CTT1057 in BCR | Prostatic Neoplasms, Prostate Cancer | P3 | Completed | 190 | Open-label | [18F]CTT1057, [68Ga]Ga-PSMA-11 |
| NCT00231998 Extension Study of Pimecrolimus Cream in Pediatric Patients With Atopic Dermatitis | Atopic Dermatitis | P3 | Completed | 240 | Open-label | Pimecrolimus |
| NCT01161264 Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011, When Administered to Adult and Elderly Subjects | Seasonal Influenza | P3 | Completed | 126 | RCT, Open-label | Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011 |
| NCT00687804 A 12 Month Core Study to Assess the Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema and a 24 Month Open-label Extension Study | Diabetic Macular Edema | P3 | Completed | 345 | RCT, Double-blind | Ranibizumab, Sham to ranibizumab |
| NCT00413049 Efficacy/Safety of Valsartan Plus Amlodipine and Amlodipine Alone in Patients With Hypertension | Hypertension | P3 | Completed | 698 | RCT, Double-blind | Valsartan/amlodipine 80/5 mg, Amlodipine 5 mg |
| NCT00604500 A Patient Handling Study of Mometasone Furoate/Formortoral Fumarate (MF/F) Metered Dose Inhaler (MDI) With an Integrated Dose Counter in Adolescent and Adult Subjects With Asthma or Chronic Obstructive Pulmonary Disease (Study P04703AM1) | Asthma, COPD | P3 | Completed | 272 | Open-label | SCH No. 418131 (Mometasone Furoate/Formoterol Furoate abbreviated MF/F ) |
| NCT01412944 Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis | Plaque-type Psoriasis | P3 | Completed | 43 | RCT, Double-blind | secukinumab 150mg, secukinumab 10mg/kg i.v. regimen |
| NCT00770081 Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study) | Diabetes Mellitus, Type 2, Renal Insufficiency | P3 | Completed | 75 | RCT, Double-blind | vildagliptin, sitagliptin |
| NCT01031628 Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients | Gastrointestinal Stromal Tumors | P3 | Terminated | 5 | RCT, Open-label | Imatinib mesylate, Imatinib mesylate, Imatinib mesylate |
| NCT01120028 Campath, Calcineurin Inhibitor Reduction and Chronic Allograft Nephropathy | Kidney Transplantation | P2P3 | Completed | 852 | RCT, Open-label | Alemtuzumab, Basiliximab, Sirolimus, Tacrolimus |
| NCT00409851 One Year Study to Evaluate the Safety of the Combination of Valsartan and Amlodipine in Patients With Hypertension | Hypertension | P3 | Completed | 1,293 | RCT, Open-label | valsartan+amlodipine |
| NCT00845728 Exacerbation Study | Chronic Obstructive Pulmonary Disease | P3 | Completed | 3,439 | RCT, Double-blind | Indacaterol 150 µg, Tiotropium |
| NCT00806195 Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants | Meningitis, Meningococcal Infection | P3 | Completed | 7,744 | RCT, Open-label | MenACWY-CRM197, DTaP (Diptheria, Tetanus, Pertussis) Vaccine, Hib (Haemophilus influenza b) Vaccine, IPV (Inactivated Polio Vaccine) Vaccine, Pneumococcal conjugate Vaccine, MMR (Measles, Mumps, and Rubella) Vaccine, Varicella Vaccine, Hepatitis A Virus |
| NCT03100500 A Long-term Safety Study of QMF149 in Japanese Participants With Asthma | Asthma | P3 | Completed | 51 | Open-label | QMF149 |
| NCT00332709 Safety/Efficacy of Letrozole Monotherapy or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer | Osteoporosis, Postmenopausal | P3 | Completed | 83 | RCT, Open-label | Letrozole, Zoledronic acid |
| NCT00351052 Steroid-Sparing Effect With Pimecrolimus in Pediatric Patients With Atopic Dermatitis | Atopic Dermatitis | P3 | Completed | 184 | RCT, Double-blind | Pimecrolimus, Placebo |
| NCT00230464 Acute Metabolic Effects of LAF 237 in Type 2 Diabetics | Type 2 Diabetes Mellitus | P3 | Completed | 16 | RCT, Double-blind | LAF 237 |
| NCT00124748 Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity) | Leukemia, Myeloid, Chronic Phase | P3 | Terminated | 476 | RCT, Open-label | Imatinib mesylate |
| NCT00355134 Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis | Multiple Sclerosis | P3 | Completed | 1,083 | RCT, Double-blind | Fingolimod, Placebo |
| NCT03832998 Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine | Migraine | P3 | Completed | 284 | RCT, Double-blind | Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3 |
| NCT00351832 A Study To Compare the Effect of Vildagliptin Compared to Placebo in Patients With Type 2 Diabetes | Diabetes Mellitus, Type 2 | P3 | Completed | 236 | RCT, Double-blind | Vildagliptin |
| NCT01139021 One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age | Meningococcal Disease | P3 | Completed | 508 | Open-label | rMenB+OMV NZ |
| NCT02598297 Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations. | Myelofibrosis With High Molecular Risk Mutations | P3 | Terminated | 49 | RCT, Double-blind | Ruxolitinib, Ruxolitinib Placebo |
| NCT01773460 Everolimus Beyond Progress for Patients Who Had Progress Under Everolimus and Exemestane | Metastatic Breast Cancer | P3 | Terminated | 3 | RCT, Double-blind | Everolimus, Everolimus-placebo |
| NCT02064868 Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) Patients | Acute Heart Failure (AHF) | P3 | Terminated | 2,666 | RCT, Open-label | Serelaxin, Standard of Care |
| NCT01863732 Extension in AS: Sustainability of Benefits, Safety and Tolerability | Spondylitis, Ankylosing | P3 | Completed | 274 | RCT, Double-blind | Secukinumab |
| NCT00115245 Telbivudine Versus Adefovir Dipivoxil in Adults With HBegAg-Positive, Compensated Chronic Hepatitis B | Chronic Hepatitis B | P3 | Completed | — | RCT, Open-label | Telbivudine (LdT), Adefovir Dipivoxil |
| NCT00739973 Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension | Hypertension | P3 | Completed | 2,694 | RCT, Double-blind | Placebo, Aliskiren 150 mg tablet, Aliskiren 300 mg tablet, Amlodipine 5 mg capsule, Amlodipine 10 mg capsule, Aliskiren/amlodipine 150/5 mg tablet, Aliskiren/amlodipine 150/10 mg tablet, Aliskiren/amlodipine 300/5 mg tablet, Aliskiren/amlodipine 300/10 mg tablet |
| NCT01012765 Effect of Indacaterol on Inspiratory Capacity (IC) | Chronic Obstructive Pulmonary Disease | P3 | Completed | 173 | RCT, Double-blind | Indacaterol, Tiotropium, Placebo |
| NCT04807400 Study in Primary Care Evaluating Inclisiran Delivery Implementation + Enhanced Support | Atherosclerotic Cardiovascular Disease, Atherosclerotic Cardiovascular Disease Risk Equivelents | P3 | Completed | 892 | RCT, Open-label | Inclisiran, Background lipid lowering therapy |
| NCT00232076 Verification Study of Ciclosporin for Atopic Dermatitis | Severe Atopic Dermatitis | P3 | Completed | — | RCT, Double-blind | ciclosporin |
| NCT00973349 Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly Adults | Influenza | P2P3 | Completed | 2,719 | RCT, Single-blind | MF59-eH1N1_f |
| NCT00100555 A Study of the Clinical Safety, Tolerability, and Efficacy of Zoledronic Acid Compared to an Oral Bisphosphonate | Osteoporosis | P3 | Completed | 120 | RCT, Double-blind | zoledronic acid |
| NCT01357252 Vildagliptin add-on to Glimepiride Versus Placebo Added to Glimepiride in Type 2 Diabetes | Type 2 Diabetes Mellitus | P3 | Completed | 279 | RCT, Double-blind | vildagliptin, Placebo |
| NCT00391950 Maintaining Bone Strength in Men With Prostate Cancer | Prostate Cancer | P3 | Terminated | 300 | RCT, Open-label | Zoledronic acid |
| NCT01870778 Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF | Acute Heart Failure | P3 | Completed | 6,600 | RCT, Double-blind | RLX030, Placebo |
| NCT01033747 Safety and Efficacy of Deferasirox in Patients With Transfusion Dependent Iron Overload - a Non-comparative Extension Study | Liver Iron Overload | P2P3 | Completed | 70 | Open-label | Deferasirox, Deferasirox |
| NCT00975715 Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures | Partial Onset Seizures | P2P3 | Completed | 99 | RCT, Double-blind | TRI476, Placebo to TRI476, Benzodiazepines |
| NCT01680016 A Randomized, Open-label Study Comparing Two Different Rabies Vaccine Schedules in Chinese Children and Older Adults | Rabies | P3 | Completed | 644 | RCT, Open-label | Zagreb, Essen |
| NCT00329849 Safety and Immunogenicity of Meningococcal ACWY Conjugate Versus Polysaccharide Vaccine in Children 2 to 10 Years of Age | Meningococcal Disease | P3 | Completed | 1,500 | RCT, Single-blind | Meningococcal ACWY-CRM conjugate vaccine, Meningococcal ACWY-PS polysaccharide vaccine |
| NCT00239876 Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients | Renal Transplantation | P3 | Completed | 140 | RCT, Open-label | FTY720 |
| NCT02201290 A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) | Purpura, Thrombocytopenic, Idiopathic | P3 | Completed | 9 | Open-label | Eltrombopag Tablets, Eltrombopag PfOS |
| NCT00003884 Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone | Hypercalcemia of Malignancy, Lung Cancer | P3 | Completed | 600 | RCT | zoledronic acid |
| NCT00171418 Assessment of the Effects of Tegaserod in the Management of Gastroesophageal Reflux Disease (GERD) in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs). | Gastroesophageal Reflux Disease (GERD) | P3 | Completed | 54 | RCT, Open-label | Tegaserod |
| NCT01171976 Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus | Diabetic Macular Edema | P3 | Completed | 373 | RCT, Single-blind | Ranibizumab |
| NCT00267189 RESCUE Study - Everolimus in Liver Transplantation Recipients With Renal Insufficiency | Liver Transplantation | P3 | Completed | 145 | RCT, Open-label | Everolimus, Calcineurin inhibitors (CNI), Mycophenolate acid (MPA)/ Azathioprine (AZA), Steroids |
| NCT00242580 A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib | Macular Degeneration, Choroidal Neovascularization | P3 | Completed | 111 | RCT, Double-blind | Verteporfin photodynamic therapy, Pegaptanib, Triamcinolone acetonide |
| NCT02792218 Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis | Relapsing Multiple Sclerosis | P3 | Completed | 930 | RCT, Double-blind | Ofatumumab subcutaneous injection, Teriflunomide-matching placebo capsules, Teriflunomide capsule, Matching placebo of ofatumumab subcutaneous injections |
| NCT00658320 Concentration Controlled Everolimus With Reduced Dose Cyclosporine Versus Mycophenolate Mofetil With Standard Dose Cyclosporine in de Novo Renal Transplant Adult Recipients Treated With Basiliximab and Corticosteroids | Kidney Transplantation | P3 | Completed | 122 | RCT, Open-label | Everolimus, Mycophenolate mofetil (MMF), Basiliximab, Cyclosporine A, Corticosteroid |
| NCT01093846 38 Week Extension Study to CAIN457C2303 | Uveitis | P3 | Terminated | 59 | RCT, Double-blind | AIN457, AIN457, Placebo AIN457 |
| NCT00856297 Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine | Meningococcal Meningitis | P3 | Completed | 389 | Open-label | MenACWY-CRM conjugate vaccine, Licensed comparator |
| NCT01572727 A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation | Breast Cancer | P2P3 | Completed | 416 | RCT, Double-blind | Paclitaxel, BKM120 matching placebo, BKM120 |
| NCT00235391 Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload | Thalassemia, Sickle Cell Disease | P3 | Completed | 1,683 | Open-label | Deferasirox |
| NCT00413829 Immediate Effects of Lucentis® in Conjunction With Photodynamic Therapy With Visudyne® in Exudative AMD(IECOMB) | Age Related Macular Degeneration | P2 | Completed | 20 | Open-label | Intravitreal ranibizumab with photodynamic therapy |
| NCT01393340 Clinical and Biological Effects of Anti-IgE (Omalizumab) in Patients With Bilateral Nasal Polyposis and Asthma | Nasal Polyposis, Asthma | P2 | Completed | 23 | RCT, Double-blind | Omalizumab, Placebo |
| NCT00784446 First-line Therapy of Stage IV Colorectal Cancer | Stage IV Colorectal Cancer | P1P2 | Completed | 51 | Open-label | Oxaliplatin, Capecitabine, Bevacizumab, Imatinib |
| NCT00719264 Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer | Carcinoma, Adenocarcinoma | P2 | Completed | 365 | RCT, Open-label | RAD001(everolimus), interferon alfa-2a, bevacizumab |
| NCT02404844 Trial of BKM120/Tamoxifen-combination in Patients With HR-pos, HER2-neg Breast Cancer | Breast Cancer | P2 | Completed | 48 | Open-label | BKM120, Tamoxifen |
| NCT01520103 Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer | Her2-negative Metastatic Breast Cancer, Her2-negative Locally Advanced Breast Cancer | P2 | Completed | 139 | RCT, Open-label | Vinorebine, Everolimus, Vinorelbine |
| NCT01163227 Effect of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia | Schizophrenia Disorders | P2 | Completed | 57 | RCT, Double-blind | Placebo (single and multiple doses), AQW051 2 mg (single and multiple doses), AQW051 15mg (single and multiple doses), AQW051 100mg (single dose), and 50mg (multiple doses) |
| NCT02608268 Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies | Advanced Malignancies | P1P2 | Terminated | 252 | Open-label | MBG453, PDR001, Decitabine |
| NCT07923773 Extension Study of Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis (CDDY391A12201-extension) | Moderate to Severe Psoriatic Arthritis | P2 | Not Yet Recruiting | 88 | Open-label | DDY391 |
| NCT01064791 Efficacy, Safety, Tolerability, and Pharmacokinetics of Sotrastaurin Combined With Tacrolimus vs. a Mycophenolic Acid-tacrolimus Regimen in Renal Transplant Patients | Renal Transplantation | P2 | Completed | 298 | RCT, Double-blind | sotrastaurin (Dose 1) + tacrolimus + standard of care medications, sotrastaurin (Dose 2) + tacrolimus + standard of care medications, sotrastaurin (Dose 3) + tacrolimus + standard of care medications, mycophenolic acid + tacrolimus + standard of care medications |
| NCT01013597 Trial of LBH589 in Metastatic Thyroid Cancer | Thyroid Carcinoma | P2 | Completed | 13 | Open-label | LBH589 |
| NCT00930982 Evaluation of Cipro Inhale in Patients With Non-cystic Fibrosis Bronchiectasis | Bronchiectasis | P2 | Completed | 124 | RCT, Double-blind | Ciprofloxacin (Cipro, BAYQ3939), Placebo |
| NCT03988608 Study Assessed the Safety and Efficacy of Eltrombopag in Chinese Refractory or Relapsed Severe Aplastic Anemia (SAA) Subjects. | Aplastic Anemia | P2 | Completed | 20 | Open-label | Eltrombopag |
| NCT00557440 Investigation of the 24 Hour Forced Expiratory Flow in 1 Second (FEV1) Profile of a Single Dose of Indacaterol/Mometasone Delivered Via the TWISTHALER® Device in Adult Patients With Persistent Asthma | Asthma | P2 | Completed | 37 | RCT, Double-blind | fluticasone propionate/salmeterol, indacaterol maleate / mometasone furoate, placebo to indacaterol/mometasone, placebo to fluticasone propionate/salmeterol |
| NCT00537524 Immunogenicity, Safety and Tolerability of Two Doses of a Pre-pandemic Influenza Vaccine in Participants Aged 6 Months to 17 Years | Prophylaxis of Avian Influenza | P2 | Completed | 471 | RCT, Single-blind | H5N1 Influenza Vaccine, H5N1 Influenza Vaccine |
| NCT04812483 Immunomodulation With Eltrombopag in ITP | Primary Immune Thrombocytopenia (ITP) | P2 | Completed | 2 | RCT, Open-label | Eltrombopag (Revolade®), standard therapy (without eltrombopag): HD-DXM |
| NCT00788775 Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma | Mucosal Lentiginous Melanoma, Acral Melanoma | P2 | Completed | 20 | Open-label | Nilotinib |
| NCT00216112 Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer | Ovarian Cancer | P2 | Completed | 23 | Open-label | Imatinib Mesylate, Docetaxel |
| NCT00411619 Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex | Tuberous Sclerosis, Subependymal Giant Cell Astrocytoma | P1P2 | Completed | 28 | Open-label | Everolimus |
| NCT00987545 Efficacy 2 Part Study of Identification of Keloid Biomarkers and Effect of QAX576 on Keloid Recurrence | Keloids | P2 | Terminated | 3 | RCT, Double-blind | QAX576, QAX576 placebo |
| NCT00743288 Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma | Multiple Myeloma | P1P2 | Completed | 40 | Open-label | Melphalan, Panobinostat |
| NCT01528501 Histone Deacetylases - Gastric Cancer (HDAC-GaCa-2008) | Metastatic Gastric Cancer | P2 | Terminated | 28 | Open-label | Panobinostat (LBH589) |
| NCT00303251 Safety of TKI258 in Advanced/Metastatic Melanoma Subjects | Melanoma | P1P2 | Completed | 47 | Open-label | TKI258 |
| NCT02300545 Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy | Sarcoma, Soft Tissue, Soft Tissue Sarcoma | P2 | Completed | 56 | Open-label | Pazopanib |
| NCT01703169 Efficacy and Safety of Eltrombopag In Patients With Severe and Very Severe Aplastic Anemia | Severe Aplastic Anemia, Very Severe Aplastic Anemia | P2 | Completed | 13 | Open-label | Eltrombopag |
| NCT04795466 Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Disease | Mild Cognitive Impairment, Alzheimer Disease | P2 | Terminated | 34 | RCT, Double-blind | Canakinumab |
| NCT02160041 BGJ398 for Patients With Tumors With FGFR Genetic Alterations | Solid Tumor, Hematologic Malignancies | P2 | Terminated | 84 | Open-label | BGJ398 |
| NCT01028222 A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation | Melanoma | P2 | Completed | 55 | Open-label | Nilotinib, DTIC |
| NCT03387475 Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk MDS Resistant or Relapsing After ESA Agents | Myelodysplasia | P2 | Completed | 39 | Open-label | Deferasirox |
| NCT00171951 Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's Disease | Cushing Disease | P2 | Completed | 19 | Open-label | Pasireotide |
| NCT00582556 Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy | Prostate Cancer | P2 | Completed | 44 | RCT, Open-label | Zometa, zometa, Zometa |
| NCT00987870 Safety and Efficacy of BFH772 in Psoriasis Patients | Psoriasis, Arthritis | P1P2 | Completed | 15 | RCT, Double-blind | BFH772, Placebo, BFH772, Placebo, calcipotriol/betamethasone |
| NCT01660295 Pharmacokinetics of Certoparin in Subjects With Renal Insufficiency and Healthy Subjects | Renal Insufficiency | P1P2 | Completed | 32 | Open-label | Certoparin 3,000 IU Once Daily, Certoparin 3,000 IU Twice a Day, Certoparin 8,000 IU Once Daily, Certoparin 8,000 IU Twice a Day |
| NCT00827567 Trial of RAD001 in Triple Negative Metastatic Breast Cancer | Breast Cancer | P2 | Terminated | 6 | Open-label | RAD 001 |
| NCT01207492 Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor | Pigmented Villonodular Synovitis, Diffuse-type Giant Cell Tumor | P2 | Completed | 17 | Open-label | nilotinib |
| NCT02270944 Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent Vaccine | Infections, Streptococcal, Streptococcal Infections | P2 | Completed | 1,053 | RCT, Double-blind | GBS Vaccine, GBS Vaccine |
| NCT02588339 Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention | Graft Versus Host Disease, GVHD | P2 | Completed | 42 | Open-label | Panobinostat, Sirolimus, Tacrolimus |
| NCT01072175 Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212 | Cancer | P2 | Completed | 430 | Open-label | GSK2118436, GSK1120212 |
| NCT02342600 SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor) | Gastrointestinal Stromal Tumors | P2 | Withdrawn | — | Open-label | Pazopanib, Trametinib |
| NCT00247650 Comparison Study of Letrozole Alone or Letrozole With Zoledronic Acid in Early Breast Cancer, Neoadjuvant Therapy | Breast Cancer | P2 | Completed | 190 | RCT, Open-label | Zoledronic Acid; Letrozole |
| NCT01423110 Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis | Sporadic Inclusion Body Myositis | P2 | Completed | 14 | RCT, Double-blind | BYM338, Placebo |
| NCT01446289 Immune Response Induced by a Vaccine Against Group B Streptococcus and Safety in Pregnant Women and Their Offsprings | Streptococcal Infection, Gram-positive Bacterial Infection | P2 | Completed | 86 | RCT, Single-blind | Group B Streptococcus Trivalent Vaccine, Placebo |
| NCT01802879 Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Continue to Benefit From the Treatment as Judged by the Investigator | Hematologic Neoplasms | P2 | Completed | 9 | Open-label | Panobinostat |
| NCT01480791 Aliskiren vs Hydrochlorothiazide in Hypertensive Type II Diabetic Patients on Resistance Arteries | Hypertension, Diabetes | P2 | Withdrawn | — | RCT, Double-blind | Aliskiren vs. hydrochlorothiazide, Hydrochlorothiazide |
| NCT00461773 Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer | Hormone-Sensitive Breast Cancer, Breast Cancer | P2 | Terminated | 5 | RCT, Open-label | Letrozole, Bevacizumab |
| NCT01271920 Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab | Advanced HER2-positive Breast Cancer | P1P2 | Completed | 45 | Open-label | AUY922, Trastuzumab |
| NCT03610724 Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients | Non-Hodgkin Lymphoma | P2 | Completed | 34 | Open-label | Tisagenlecleucel, lymphodepleting chemotherapy, Bridging Therapy |
| NCT00140803 Study Of Combined VISUDYNE Therapy With Kenalog In CNV Secondary To Age-Related Macular Degeneration | Age-Related Macular Degeneration | P2 | Completed | 106 | RCT, Single-blind | Visudyne, Kenalog |
| NCT00649883 Safety and Immunogenicity of Two 0.25 mL or 0.5 mL Doses of Two Different Influenza Vaccines in Healthy Children Aged 6 to <60 Months | Influenza | P2 | Completed | 360 | RCT, Single-blind | Influenza Trivalent Inactivated vaccines Novartis, Influenza Trivalent Inactivated vaccines |
| NCT00704483 Efficacy of SBR759 in Lowering Serum Phosphate Levels in Chronic Kidney Disease Patients on Hemodialysis | Hyperphosphatemia Patients With Chronic Kidney Disease on 3x/Week Replacement Therapy | P2 | Completed | 321 | RCT, Open-label | SBR759, Sevelamer HCl, SBR759, Sevelamer HCl |
| NCT02927366 Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients | Pulmonary Arterial Hypertension | P2 | Terminated | 8 | RCT, Double-blind | QCC374, Placebo Matching |
| NCT00912340 Phase II Trial of EVEROLIMUS ± Trastuzumab in Hormone-Refractory Metastatic Breast Cancer | Breast Cancer | P2 | Completed | 70 | RCT, Open-label | Everolimus, Trastuzumab |
| NCT01958112 GSK1120212+GSK2141795 for Cervical Cancer | Cervical Cancer | P2 | Terminated | 14 | Open-label | GSK1120212 (trametinib), GSK2141795 |
| NCT03944707 Study of Efficacy and Safety of LOU064 in Inadequately Controlled Asthma Patients | Asthma | P2 | Terminated | 76 | RCT, Double-blind | LOU064 100 mg, Placebo |
| NCT06362759 A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP | Chronic Kidney Diseases, Chronic Kidney Insufficiency | P2 | Completed | 143 | RCT, Double-blind | TOUR006 - 50 MG, TOUR006 - 25 MG, TOUR006 - 15 MG |
| NCT02294786 Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer | Cancer | P2 | Terminated | 62 | RCT, Open-label | Lapatinib, Capecitabine, Octreotide |
| NCT01529554 Controlled Level EVERolimus in Acute Coronary Syndromes | Acute Coronary Syndromes | P1P2 | Completed | 150 | RCT, Double-blind | Everolimus, Placebo |
| NCT01528345 Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer | Metastatic Breast Cancer | P2 | Terminated | 97 | RCT, Double-blind | Dovitinib, Fulvestrant, Dovitinib Placebo |
| NCT00447694 Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment | Beta-thalassemia, Iron Overload | P2 | Completed | 30 | Open-label | Deferasirox |
| NCT04391894 A Study to Assess the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye Disease | Dry Eye | P2 | Completed | 718 | RCT, Double-blind | ECF843 |
| NCT01524341 Efficacy, Safety, Tolerability and Pharmacokinetics of KAE609 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection | Malaria | P2 | Completed | 27 | Open-label | KAE609 |
| NCT01024946 Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity | Malignant Pleural Mesothelioma | P2 | Completed | 11 | Open-label | everolimus |
| NCT02290431 Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma | Relapse/Refractory Multiple Myeloma | P2 | Completed | 31 | Open-label | LBH589 (panobinostat), bortezomib, dexamethasone |
| NCT04566445 HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005 | Dry Age-related Macular Degeneration | P2 | Terminated | 255 | RCT, Double-blind | GT005 |
| NCT01163929 A Study to Look at the Combination of Chemotherapy, Trastuzumab and RAD001 in HER2 Positive Breast Cancer | Breast Cancer | P2 | Withdrawn | — | RCT, Open-label | paclitaxel |
| NCT00781261 Osteonecrosis of the Hip and Bisphosphonate Treatment | Osteonecrosis | P2 | Unknown | 120 | RCT, Double-blind | Zoledronic Acid, Placebo |
| NCT01194908 Re-expression of ER in Triple Negative Breast Cancers | Breast Cancer, Breast Tumors | P1P2 | Terminated | 5 | Open-label | Decitabine, LBH589, Tamoxifen |
| NCT01438996 Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults | Typhoid Fever | P2 | Completed | 51 | Open-label | NVGH Vi-CRM197 |
| NCT01596062 Pharmacodynamics, Efficacy and Safety of Basiliximab 40 or 80 mg in Combination With Ciclosporine Microemulsion or Everolimus, in Adult Low Risk de Novo Renal Transplant Recipients (IDEALE Study) | Renal Transplantation | P2 | Completed | 16 | RCT, Open-label | Simulect®, Neoral®, Certican®, Myfortic®, Corticosteroids |
| NCT02920892 AFQ056 for Language Learning in Children With FXS | Fragile X Syndrome | P2 | Completed | 110 | RCT, Double-blind | AFQ056, Placebo |
| NCT00381615 Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study | Healthy | P2 | Completed | 147 | RCT, Open-label | rMenB, rMenB+OMV, DTaP-Hib-IPV, PC7, MenC-CRM, MenC-Hib, MMR |
| NCT04139317 Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50% | Non-small Cell Lung Cancer (NSCLC) | P2 | Terminated | 76 | RCT, Open-label | Capmatinib, Pembrolizumab |
| NCT01349660 Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme | Glioblastoma Multiforme | P1P2 | Completed | 88 | Open-label | Bevacizumab, BKM120 |
| NCT01140568 Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas | Glioma | P2 | Completed | 38 | Open-label | nilotinib |
| NCT01449591 Safety, Tolerability and Efficacy of BFH772 in Rosacea Patients | Erythemato-telangiectatic Rosacea | P2 | Completed | 36 | RCT, Double-blind | BFH772 1% ointment, Vehicle ointment, Noritate® 1% cream |
| NCT04868968 Study of Safety, Tolerability and Efficacy of DFV890 in Participants With Familial Cold Auto-inflammatory Syndrome (FCAS) | Familial Cold Autoinflammatory Syndrome | P2 | Completed | 4 | Open-label | DFV890 |
| NCT06881823 Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC | Prostate Cancer | P1P2 | Withdrawn | — | RCT, Open-label | AAA602, AAA802, Gallium (68Ga) gozetotide, Piflufolastat (18F), Flotufolastat F 18, 18F-PSMA-1007 |
| NCT00172068 Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow | Primary Breast Cancer | P2 | Terminated | 96 | RCT, Open-label | Zoledronic acid + Calcium/Vitamin D |
| NCT06155994 68Ga-DOTA-MGS5 PET/CT in Patients With Advanced Neuroendocrine Tumours | Neuroendocrine Tumors | P1P2 | Completed | 12 | Open-label | 68Ga-DOTA-MGS5 |
| NCT01327053 A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma | Basal Cell Carcinoma | P2 | Completed | 230 | RCT, Double-blind | LDE225 |
| NCT00072709 Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | P2 | Completed | 551 | RCT, Double-blind | TCH346 |
| NCT00732771 Proof-of-concept for the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism | Primary Hyperaldosteronism | P2 | Completed | 12 | Single-blind | LCI699 |
| NCT03280030 A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML | Acute Myeloid Leukemia | P2 | Completed | 67 | RCT, Double-blind | Midostaurin, Placebo |
| NCT00709761 Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC | Neoplasms, Breast | P2 | Completed | 60 | Open-label | Lapatinib/nab-Paclitaxel |
| NCT02145715 Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple Myeloma | Multiple Myeloma | P1P2 | Unknown | 54 | Open-label | Velcade, Thalidomide, Dexamethasone, Panobinostat |
| NCT04410523 Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma | Asthma | P2 | Terminated | 335 | RCT, Double-blind | CSJ117, Placebo |
| NCT00748813 Safety and Immunogenicity of Surface Antigen, Inactivated, Influenza Vaccine Using the Strain Composition 2008/2009 | Seasonal Influenza | P2 | Completed | 133 | Open-label | Influenza Vaccine, Formulation 2008-2009 |
| NCT02460224 Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. | Advanced Solid Tumors | P1P2 | Completed | 490 | Open-label | LAG525, PDR001 |
| NCT00885196 A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque Psoriasis | Moderate and Severe Plaque Psoriasis | P2 | Completed | 336 | RCT, Double-blind | Placebo, AEB071 |
| NCT00457964 RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM | Tuberous Sclerosis, Lymphangioleiomyomatosis | P1P2 | Completed | 36 | Open-label | RAD001 |
| NCT01546532 Renal Hemodynamic Effects of RLX030A in Subjects With Chronic Heart Failure (CHF) | Chronic Heart Failure (CHF) | P2 | Completed | 118 | RCT, Double-blind | RLX030, Placebo |
| NCT04905316 A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer | Non-small Cell Lung Cancer | P2 | Completed | 41 | Open-label | Canakinumab, Durvalumab, Chemotherapy |
| NCT00136409 A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML) | Myelofibrosis, Myeloid Metaplasia | P2 | Completed | 34 | Open-label | Imatinib mesylate |
| NCT00942734 Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma | Head And Neck Cancer | P2 | Completed | 49 | Open-label | Erlotinib, RAD001 |
| NCT04191421 Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer | Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8 | P1P2 | Completed | 35 | Open-label | Siltuximab, Spartalizumab |
| NCT02038816 Azacitidine Plus Deferasirox (ICL670) in Higher Risk Myelodysplastic Syndromes (MDS) | Myelodysplastic Syndromes | P2 | Terminated | 1 | RCT, Open-label | Deferasirox + Azacitidine, Azacitidine |
| NCT00639392 Phase 1 Study of Zoledronic Acid in Sickle Cell Disease | Sickle Cell Disease | P1P2 | Withdrawn | — | RCT, Double-blind | Placebo, Zoledronic Acid |
| NCT02891395 Efficacy and Safety of Nilotinib in Patients With a Chronic Disease of the Graft Against the Host | Graft Versus Host Disease | P2 | Completed | 65 | Open-label | Imatinib Mesylate and Nilotinib |
| NCT00746330 Single Dose Study of the Effect of Formoterol Fumarate in Combination With Mometasone Furoate Inhaled Via a Pressurized Metered Dose Inhaler (pMDI) in Children Aged 5-11 Years Old With Persistent Asthma | Asthma | P2 | Completed | 32 | RCT, Double-blind | Mometasone furoate/formoterol fumarate (MFF), Formoterol fumarate 12 μg pMDI (F12M), Formoterol fumarate 12 μg DPI (F12D), Placebo to F12D, Placebo to F12M/MFF |
| NCT02379637 Study to Evaluate the Efficacy of N-acetylcysteine (NAC) in the Treatment of the Common Cold and Cough | Common Cold Associated With Cough | P2 | Completed | 70 | RCT, Double-blind | N-acetylcysteine, Placebo |
| NCT01491672 Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma | P2 | Completed | 134 | Open-label | RAD001 |
| NCT00138632 Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD) | Wet Age-Related Macular Degeneration | P1P2 | Completed | 50 | RCT, Double-blind | PTK787, PTK787, Placebo |
| NCT01610336 A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment | Non-small Cell Lung Cancer | P2 | Completed | 161 | Open-label | INC280, Gefitinib |
| NCT02398500 Safety Tolerability and Efficacy of Intravitreal LMG324 in the Treatment of Neovascular Age-Related Macular Degeneration | Age-related Macular Degeneration (AMD) | P1P2 | Terminated | 25 | RCT, Double-blind | LMG324, Ranibizumab 0.5 mg, Sham |
| NCT04323436 Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations | Carcinoma, Non-Small-Cell Lung | P2 | Terminated | 31 | RCT, Double-blind | Spartalizumab, Capmatinib, spartalizumab placebo |
| NCT02531932 Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer | Breast Cancer | P2 | Completed | 64 | RCT, Open-label | Carboplatin, Everolimus |
| NCT01132664 Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer | Metastatic Breast Cancer, HER2+ Breast Cancer | P1P2 | Terminated | 72 | Open-label | BKM120, Trastuzumab, Capecitabine |
| NCT00171249 An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia | Philadelphia Positive Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia | P2 | Completed | 293 | Open-label | STI571 400 mg, STI571 600 mg |
| NCT00501852 Efficacy and Safety of Four Doses of Glycopyrronium Bromide (NVA237) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), in Comparison to an Active Comparator Tiotropium | Chronic Obstructive Pulmonary Disease | P2 | Completed | 83 | RCT, Double-blind | NVA237, Placebo, Tiotropium |
| NCT04437368 EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005 | Dry Age-related Macular Degeneration | P2 | Terminated | 98 | RCT, Double-blind | GT005 |
| NCT02002689 LDE225 for Patients With PTCH1 or SMO Mutated Tumors | PTCH1 or SMO Activated Solid and Hematologic Tumors | P2 | Terminated | 10 | Open-label | LDE225 |
| NCT02291913 Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer | Breast Cancer | P2 | Completed | 48 | Open-label | Everolimus, Exemestane, Tamoxifen, Fulvestrant, Anastrozole, Letrozole, Toremifine |
| NCT01116440 A Safety & Efficacy Study of BGS649 in Women With Refractory Endometriosis | Pelvic Pain Associated With Refractory Endometriosis | P2 | Terminated | 27 | RCT, Double-blind | BGS649, Placebo |
| NCT02750215 A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor | Malignant Non-small Cell Neoplasm of Lung Stage IV | P2 | Completed | 20 | Open-label | Capmatinib (INC280) |
| NCT03664518 to Evaluate the Efficacy and Safety of Eltrombopag for Immune Thrombocytopenia With Chronic HBV Infection | Thrombocytopenia Purpura, Chronic HBV Infection | P2 | Completed | 48 | Open-label | Eltrombopag |
| NCT04035668 A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome | Sjögren Syndrome | P2 | Terminated | 73 | RCT, Double-blind | Remibrutinib, Placebo |
| NCT00316615 Safety and Immunogenicity of a Inactivated Influenza Vaccine When Administered to Non Elderly Adults and Elderly Subjects. | Influenza Disease | P2 | Completed | 100 | Open-label | influenza vaccine |
| NCT00291135 Protocol for Women at Increased Risk of Developing Breast Cancer | Breast Cancer | P2 | Completed | 42 | Open-label | letrozole |
| NCT01964235 Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma | Advanced Hepatocellular Carcinoma | P2 | Withdrawn | — | RCT, Double-blind | INC280, Placebo |
| NCT00481676 Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria | Chronic Urticaria | P2 | Completed | 49 | RCT, Double-blind | Omalizumab 75-375 mg, Placebo to omalizumab, Loratadine, Clemastine |
| NCT03499899 A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer | Triple-negative Breast Cancer | P2 | Completed | 88 | RCT, Open-label | LAG525, PDR001, Carboplatin |
| NCT01167335 Evaluate the Efficacy of BGG492 as Adjunctive Treatment in Patients With Refractory Partial Onset Seizures | Partial Onset Seizures | P2 | Withdrawn | — | RCT, Double-blind | BGG492, Placebo |
| NCT00230074 A Long-term Extension Study of TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis(ALS) | Amyotrophic Lateral Sclerosis | P2 | Completed | 350 | RCT, Double-blind | TCH346 |
| NCT03781414 Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension | Liver Transplant Rejection | P2 | Terminated | 129 | RCT, Open-label | CFZ533, Tacrolimus - MMF - corticosteroids |
| NCT00276926 Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias | Hypereosinophilic Syndrome, Chronic Eosinophilic Leukemia (CEL) | P2 | Unknown | — | Open-label | STI571 |
| NCT01676714 Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer | Non-Small Cell Lung Cancer, Colorectal Cancer | P2 | Completed | 10 | Open-label | Dovitinib |
| NCT02086552 Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma | Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | P2 | Completed | 28 | Open-label | Lenalidomide, Sonidegib |
| NCT01336634 Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer. | Cancer | P2 | Completed | 177 | Open-label | Dabrafenib, Trametinib |
| NCT00448149 Phase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney Cancer | Carcinoma, Renal Cell | P1P2 | Completed | 55 | Open-label | RAD001, Sorafenib |
| NCT01109940 Safety and Tolerability of AIN457 in Adults (18-65 Years) With Moderate to Severe Ankylosing Spondylitis | Ankylosing Spondylitis | P2 | Completed | 39 | Open-label | AIN457A |
| NCT01365468 Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1) | Plexiform Neurofibroma Associated With Neurofibromatosis Type 1 | P2 | Terminated | 9 | Open-label | Everolimus (RAD001) |
| NCT01628913 Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors | Pancreatic Neuroendocrine Tumors (pNET) | P2 | Terminated | 62 | RCT, Open-label | BEZ235, Everolimus |
| NCT02000882 STAR Cape+BKM120 MBC With Brain Met | Brain Metastases, Breast Cancer | P2 | Completed | 10 | Open-label | BKM120, capecitabine, Trastuzumab |
| NCT00451035 Efficacy and Safety of LBH589 in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Chronic Phase | Chronic Myeloid Leukemia in Chronic Phase | P2 | Terminated | 29 | Open-label | LBH589 |
| NCT01911546 Role of Everolimus in Highly Sensitized Patients | Highly-sensitized Kidney Transplant Recipients | P2 | Completed | 20 | Open-label | everolimus + low-dose tacrolimus |
| NCT05124925 Biopsy Based Study to Understand Mechanism of Action of Ianalumab in Salivary Glands and Explore Relationships With Clinical Assessments. | Sjogren Syndrome | P2 | Completed | 21 | Open-label | Ianalumab |
| NCT03517540 Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis | Non-alcoholic Steatohepatitis (NASH) | P2 | Completed | 193 | RCT, Double-blind | Tropifexor (LJN452), Cenicriviroc (CVC) |
| NCT01390350 Ilaris® Effects in Schnitzler Syndrome (ILESCH) | Schnitzler Syndrome | P2 | Completed | 20 | RCT, Double-blind | Canakinumab, Placebo |
| NCT01148797 Evaluate the Safety and Efficacy of Canakinumab in Pediatric Patients With Colchicine Intolerant or Colchicine Resistant Familial Mediterranean Fever (FMF) | Colchicine Resistant/Intolerant Familial Mediterranean Fever | P2 | Completed | 15 | Open-label | Canakinumab |
| NCT01452113 Effect of Autonomic Neuropathy on the Efficacy of a DPP-IV Inhibitor (Galvus) Therapy | Diabetes Mellitus | P2 | Completed | 21 | Open-label | Vildagliptin |
| NCT03765788 A Placebo-controlled Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab in Giant Cell Arteritis | Giant Cell Arteritis | P2 | Completed | 52 | RCT, Double-blind | Secukinumab 300 mg, s.c., Prednisolone, Placebo |
| NCT04161118 TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma | Non Hodgkin Lymphoma | P2 | Terminated | 3 | Open-label | CTL019 |
| NCT01279473 Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study) | Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia | P1P2 | Completed | 42 | Open-label | Nilotinib |
| NCT00116376 Study of AEE788 in Patients With Recurrent/Relapse Glioblastoma Multiforme (GBM) | Glioblastoma Multiforme | P1P2 | Completed | 64 | Open-label | AEE788 |
| NCT01948817 Deferasirox BID (Twice a Day) in Transfusion Dependent Thalassemia Patients With Inadequate Response to High Doses | Focus on Transfusion Dependent Thalassemia Patients Who Are Inadequate Responders to Deferasirox > 35mg/kgQD | P2 | Withdrawn | — | Open-label | Deferasirox |
| NCT00768040 Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema | Diabetic Macular Edema | P2 | Terminated | 39 | RCT, Double-blind | Aliskiren, Placebo |
| NCT00342940 Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Subjects 18 Years of Age or Older | Influenza | P2 | Withdrawn | — | Open-label | influenza surface antigen inactivated vaccine |
| NCT02017860 Study to Collect and Assess Long-term Safety of Everolimus in Patients Who Are on Everolimus Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator. | Neoplasms | P2 | Completed | 4 | Open-label | Everolimus |
| NCT01254227 Efficacy and Safety of Deferasirox in Combination With Deferoxamine Followed by Deferasirox Monotherapy in Severe Cardiac Iron Overload | Cardiac Iron Overload | P2 | Completed | 60 | Open-label | Deferasirox and Deferoxamine |
| NCT01294579 Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL) | Lymphoma, Non-Hodgkin | P2 | Completed | 49 | Open-label | Ofatumumab, Bendamustine |
| NCT01090973 Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL) | Non-Hodgkin's Lymphoma | P2 | Terminated | 1 | Open-label | LBH589 |
| NCT03100058 A Study to Evaluate the Change in Weight After 24 Weeks Treatment With LIK066 in Obese or Overweight Adults | Obesity, Overweight | P2 | Completed | 460 | RCT, Double-blind | LIK066, Placebo |
| NCT06430671 Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis | Relapsing-remitting Multiple Sclerosis (RRMS) | P1 | Completed | 11 | Open-label | CLS12311 low, CLS12311 medium, CLS12311 high, uncoupled RBCs |
| NCT00969046 Dose-Escalation Study in Advanced Colon Cancer Patients | Colon Cancer | P1 | Completed | 60 | RCT, Open-label | EPO906 (patupilone) |
| NCT05330273 Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Efavirenz | Malaria | P1 | Completed | 14 | Open-label | Ganaplacide, Efavirenz |
| NCT02227940 Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer | Advanced Malignant Solid Neoplasm, ALK Positive | P1 | Completed | 38 | Open-label | Ceritinib, Cisplatin, Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation |
| NCT00703703 Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects | Healthy | P1 | Completed | 117 | RCT, Double-blind | Darifenacin, Tolterodine, Placebo |
| NCT02997969 Safety and Immune Response to a Clade C DNA HIV Vaccine | HIV Infections | P1 | Completed | 132 | RCT, Double-blind | DNA-HIV-PT123 vaccine, Protein/MF59 vaccine, Placebo |
| NCT00942682 Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors | Neuroendocrine Tumor, Carcinoid Tumor | P1 | Completed | 21 | Open-label | Sorafenib, RAD001 |
| NCT03434262 SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors | Anaplastic Astrocytoma, Anaplastic Ependymoma | P1 | Completed | 68 | Open-label | Gemcitabine, ribociclib, sonidegib, trametinib, filgrastim |
| NCT00442741 Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced Malignancies (Extension) | Solid Tumors | P1 | Withdrawn | — | Open-label | Patupilone, Patupilone + Omeprazole |
| NCT02182622 LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel | Prostate Cancer | P1 | Withdrawn | — | Open-label | Docetaxel, Prednisone, LDE225 |
| NCT00967928 Everolimus Dose Finding Study for Stage IV or Recurrent Cervical Cancer | Cervical Cancer | P1 | Withdrawn | — | Open-label | RAD001, Cisplatin |
| NCT03574545 Study Comparing Two VAY736 Drug Products in Patients With Rheumatoid Arthritis | Rheumatoid Arthritis | P1 | Completed | 48 | RCT, Open-label | ianalumab |
| NCT00535951 Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma | Carcinoma, Non-Small-Cell Lung, Mesothelioma | P1 | Completed | 18 | Open-label | LBH589 |
| NCT02078609 A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS) | AML and High Risk MDS | P1 | Completed | 70 | Open-label | LGH447, LGH447 + midostaurin |
| NCT04330664 Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2) | Advanced Cancer, Metastatic Cancer | P1 | Completed | 86 | Open-label | MRTX849, TNO155 |
| NCT03114319 Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors | Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC), KRAS G12-mutant NSCLC | P1 | Terminated | 227 | Open-label | TNO155, TNO155 in combination with EGF816 (nazartinib) |
| NCT03876028 Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients | Diffuse Large B-cell Lymphoma | P1 | Terminated | 10 | Open-label | Tisagenlecleucel, Ibrutinib |
| NCT01469572 Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases | Neuroendocrine Tumors | P1 | Completed | 13 | Open-label | Pasireotide, Everolimus |
| NCT02422589 A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors | ALK-positive Advanced Tumors | P1 | Completed | 33 | Open-label | ceritinib, warfarin, midazolam |
| NCT02974725 A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma | Non-Small Cell Lung Cancer, Melanoma | P1 | Terminated | 241 | Open-label | LXH254, LTT462, Trametinib, Ribociclib |
| NCT05472220 Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma | Solid Tumors, Adult, PIK3CA Mutation-Related Tumors | P1 | Withdrawn | — | Open-label | Alpelisib, Carboplatin, Hyperpolarized Carbon-13 (13C) Pyruvate |
| NCT04612062 A First-in-Human Study of CEE321 in Adult Subjects | Atopic Dermatitis | P1 | Completed | 28 | Open-label | CEE321 |
| NCT00503360 Tolerability, Safety and Efficacy of SAD448 in Subjects With Ocular Hypertension | Ocular Hypertension | P1 | Completed | 80 | RCT, Double-blind | SAD448 |
| NCT02240719 Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer | Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma | P1 | Completed | 20 | Open-label | everolimus, bendamustine hydrochloride |
| NCT03696771 Study to Determine Safety and Dose of NJH395 in Non-breast HER2+ Advanced Cancer | NON-breast HER2+ Malignancies | P1 | Completed | 18 | Open-label | NJH395 |
| NCT01429337 PK and Safety of Midostaurin in Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function | Hepatic Impairment | P1 | Completed | 43 | Open-label | Midostaurin, Midostaurin |
| NCT02323139 A Study of LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients | MDS | P1 | Completed | 23 | Open-label | Azacitidine and LDE255 |
| NCT01285466 A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab | Metastatic or Locally Advanced Solid Tumors | P1 | Completed | 110 | Open-label | BEZ235 + paclitaxel, BKM120 + paclitaxel, BEZ235 + paclitaxel + trastuzumab, BKM120 + paclitaxel + trastuzumab |
| NCT01898845 A Phase I Study of LEE011 in Asian Patients | Advanced Solid Tumors | P1 | Completed | 17 | Open-label | LEE011 |
| NCT01820325 Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer | Non-Small Cell Lunch Cancer | P1 | Terminated | 6 | RCT, Double-blind | Buparlisib, Buparlisib placebo, Carboplatin, Paclitaxel |
| NCT00006368 Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer | Brain and Central Nervous System Tumors, Breast Cancer | P1 | Completed | 60 | — | — |
| NCT06130540 Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR | Giant Cell Arteritis, Polymyalgia Rheumatica | P1 | Completed | 65 | RCT, Open-label | Secukinumab |
| NCT07908680 A Study to Assess the Safety, Tolerability and Pharmacokinetics of XEP527 in Patients With Stable Schizophrenia | Schizophrenia | P1 | Not Yet Recruiting | 36 | RCT, Double-blind | XEP527, Placebo |
| NCT02491281 First-in-human Single Ascending Dose Study of LNA043 in Patients Scheduled for Total Knee Replacement | Primary Osteoarthritis Patients Scheduled for Total Knee Replacement Surgery | P1 | Completed | 28 | RCT, Double-blind | LNA043, Placebo |
| NCT01727128 Pharmacokinetic Study of BKM120 in Subjects With Hepatic Impairment | Hepatic Impairment | P1 | Completed | 31 | Open-label | BKM120 |
| NCT02900664 A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) | Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma | P1 | Completed | 283 | Open-label | PDR001, ACZ885, CJM112, TMT212, EGF816 |
| NCT02586675 TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer | Breast Cancer, Breast Cancer - Female | P1 | Completed | 7 | Open-label | Tamoxifen, Ribociclib, Goserelin |
| NCT00613665 Safety and Immunogenicity of Chiron's Investigational H. Pylori Vaccine in Healthy Adults | Helicobacter Pylori, Gastritis | P1 | Completed | 113 | RCT, Single-blind | helicobacter pylori vaccine, helicobacter pylori vaccine, helicobacter pylori vaccine, helicobacter pylori vaccine, Placebo, helicobacter pylori vaccine, helicobacter pylori vaccine |
| NCT02167854 Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer | Breast Cancer | P1 | Completed | 23 | Open-label | BYL719, LJM716, TRASTUZUMAB |
| NCT01290380 A Study to Evaluate the Effects of ASA404 Alone or in Combination With Taxane-based Chemotherapies on the Pharmacokinetics of Drugs in Patients With Advanced Solid Tumor Malignancies | Solid Tumor Malignancies | P1 | Terminated | 54 | RCT, Open-label | ASA404, DMXAA, DXAA |
| NCT01428297 A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome | Healthy Volunteers, Atopic Dermatitis | P1 | Completed | 12 | RCT, Double-blind | BPR277 ointment (controlled application), Placebo (Vehicle), BPR277 ointment, Placebo (Vehicle), BPR277, Placebo (Vehicle) |
| NCT02282371 Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC) | Head and Neck Squamous Cell Cancer | P1 | Completed | 16 | Open-label | Cetuximab, BYL719 |
| NCT04635800 A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients | Macular Edema, Diabetic Macular Edema | P1 | Completed | 21 | Open-label | MHU650 |
| NCT02048787 Pharmacokinetic Study of Buparlisib in Subjects With Renal Impairment. | Renal Impairment | P1 | Completed | 19 | Open-label | Buparlisib |
| NCT02614508 Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma | P1 | Terminated | 1 | Open-label | Buparlisib, Ibrutinib, Ofatumumab |
| NCT00426140 Pharmacokinetics of Patupilone After a Single Intravenous Administration in Patients With Advance Solid Tumor Malignancies. | Advanced Malignancies, Solid Tumors | P1 | Completed | 5 | Open-label | Patupilone |
| NCT01064089 Dose Escalation of HSP990 in Japan/Korea | Advanced Solid Tumors | P1 | Terminated | 17 | Open-label | HSP990 |
| NCT04315233 Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics | Metastatic Breast Cancer, Recurrent Ovarian Carcinoma | P1 | Terminated | 12 | Open-label | Ribociclib, Belinostat |
| NCT01632358 Safety and Pharmacokinetis of TAP311 in Dyslipidemic Patients | Dyslipidaemia | P1 | Completed | 279 | Double-blind | TAP311 capsules, Placebo |
| NCT00414947 Bioequivalence of Vildagliptin Tablet Manufactured in China Compared to Imported Vildagliptin Tablet in Chinese Healthy Volunteers | Healthy | P1 | Completed | 30 | RCT, Open-label | Vildagliptin (LAF237) |
| NCT02678260 Phase I Study of PDR001 in Patients With Advanced Malignancies. | Advanced Malignancies | P1 | Completed | 18 | Open-label | PDR001 |
| NCT00613132 Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG | Glioblastoma, Gliosarcoma | P1 | Completed | 78 | Open-label | Gleevec, RAD001, and Hydroxyurea |
| NCT01854606 Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma | CD79 Mutant or ABC-subtype Diffuse Large B-Cell Lymphoma | P1 | Completed | 31 | Open-label | AEB071, Everolimus |
| NCT00420615 Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced Malignancies | Solid Tumors | P1 | Completed | 34 | RCT, Open-label | Patupilone and Omeprazole, Patupilone + Midalzolam |
| NCT01613976 A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients | Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) | P1 | Completed | 10 | Open-label | Panobinostat |
| NCT00570284 A Study to Investigate the Effect of Food on Oral LBH589 Absorption in Patients With Advanced Solid Tumors | Cancer | P1 | Completed | 36 | Open-label | LBH589 |
| NCT02375958 PCA062 in pCAD-positive Tumors. | Triple Negative Breast Cancer, Head & Neck Cancer | P1 | Completed | 47 | Open-label | PCA062 |
| NCT00586443 BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab) | Solid Tumors | P1 | Completed | 56 | Open-label | bevacizumab, everolimus, panitumumab |
| NCT00724776 Albinterferon Alfa 2b Single Dose in Japanese Chronic Hepatitis C Patients | Chronic Hepatitis C | P1 | Completed | 30 | Open-label | Albinterferon alfa 2b |
| NCT01875523 PK of Serelaxin in Severe Renal Impairment and ESRD | Renal Failure, Chronic, End-Stage Renal Disease | P1 | Completed | 36 | Open-label | Serelaxin |
| NCT00849550 Safety and Dosage Study of RAD001 (Everolimus) in Combination With Current Standard of Care to Treat Advanced Solid Tumors. | Unspecified Adult Solid Tumor, Protocol Specific, Cancer | P1 | Completed | 32 | Open-label | capecitabine/oxaliplatin/bevacizumab/RAD001 (XELOX-A-Ev) |
| NCT01336842 Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors | Solid Tumors, Non-Small Cell Lung Cancer (NSCLC) | P1 | Completed | 23 | Open-label | Panobinostat, Cisplatin, Pemetrexed |
| NCT02032810 Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma | Melanoma, Skin Cancer | P1 | Completed | 17 | Open-label | Panobinostat, Ipilimumab |
| NCT03834922 Providing Standardized Consented PROMs (Patient Reported Outcome Measures) for Improving Pain Treatment | Pain, Postoperative | Completed | 3,322 | — | — | |
| NCT05575843 Neurostatus-SMARTCARE in Comparison to Standard Neurostatus-EDSS® | Multiple Sclerosis (MS) | N/A | Completed | 101 | RCT, Single-blind | — |
| NCT00150891 Th1, Th2 and Monokine Responses as Risk Factors of Renal Transplant Rejection | Renal Failure, Chronic | Completed | 84 | — | cyclosporine A, tacrolimus, azathioprine, mycophenolate mofetil | |
| NCT05677542 Secukinumab (Cosentyx®) Effectiveness in Axial Spondyloarthritis and Psoriatic Arthritis Patients Using Artificial Intelligence (SpAINET): Spanish Multicenter, Retrospective, Real World Evidence Study | Axial Spondyloarthritis, Psoriatic Arthritis | Completed | 758 | — | secukinumab | |
| NCT01490983 Telemonitoring Study - for Chronic Myeloid Leukemia (CML) | Chronic Myeloid Leukemia | N/A | Terminated | 14 | RCT, Open-label | — |
| NCT05407740 "Association of Proteinuria and Progression of Kidney Dysfunction in Sickle Cell Disease"Disease | Change in Albumin to Creatinine Ratio and Glomerular Filtration Rate, Progression of Kidney Failure and or All-cause Mortality | Completed | 355 | — | — | |
| NCT01098786 Drug Use Investigation for Cell-culture Derived Influenza A (H1N1) Emulsion HA Vaccine | Swine-Origin Influenza A H1N1 Virus | Completed | 556 | — | Cell-derived A/H1N1 influenza HA vaccine | |
| NCT05834673 VICTORION-ASCERTAIN: Implementation Study (v-ASCERTAIN) | Atherosclerotic Cardiovascular Disease (ASCVD), Coronary Heart Disease (CHD) | N/A | Terminated | 6 | RCT, Open-label | — |
| NCT05021419 Efficacy of a Streamlined Heart Failure Optimization Protocol | Heart Failure with Reduced Ejection Fraction, Chronic Heart Failure | N/A | Completed | 60 | RCT, Open-label | — |
| NCT00424801 Effects of Intensive Long-Term Vasodilation in Hypertensive Patients With Microvascular Angina Pectoris | Microvascular Angina, Hypertension | N/A | Terminated | 10 | Open-label | Lercanidipine, Valsartan, Nicorandil, Doxazosin, Moxonidin, Pindolol, Amiloride, hydrochlorothiazide |
| NCT05073120 Survey Among Healthcare Professionals Treating Patients With Metastatic Breast Cancer in Selected European Countries to Evaluate Their Knowledge on Management of Hyperglycemia When Using Alpelisib | Breast Cancer | Completed | 103 | — | — | |
| NCT05294289 Health-related Quality of Life, Symptom Severity, and Pain Among Patients With PIK3CA-related Overgrowth Spectrum: A Mixed-methods Observational Study | PIK3CA-related Overgrowth Spectrum | Completed | 77 | — | — | |
| NCT02551224 Preference on the Feedback Mechanisms of Dose Delivery Confirmation With the Breezhaler® Device Compared to the Ellipta® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD) | Pulmonary Disease, Chronic Obstructive (COPD) | N/A | Completed | 100 | RCT, Open-label | — |
| NCT01285479 The Gilenya Pregnancy Registry | Multiple Sclerosis | Completed | 312 | — | Fingolimod | |
| NCT01592097 Exploratory Study to Assess Clinical Response to Gilenya® (Fingolimod) in Hispanics With RRMS | Multiple Sclerosis | Completed | 51 | — | — | |
| NCT07770074 A Real-World Study of Second-line Therapies Among Radioiodine-refractory Differentiated Thyroid Cancer (RAI-R DTC) Patients | Radioiodine-refractory Differentiated Thyroid Cancer | Not Yet Recruiting | 200 | — | — | |
| NCT01442194 Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies | Multiple Sclerosis | Completed | 3,076 | — | other disease-modifying therapy, Fingolimod | |
| NCT02194803 Observation of Treatment Patterns With Lucentis in Approved Indications | Neovascular AMD, Visual Impairment Due to DME, Visual Impairment Due to Macular Oedema Secondary to Branch or Central RVO, Visual Impairment Due to CNV | Completed | 5,778 | — | — | |
| NCT01380288 Cognitive Changes in Alzheimer's Disease Patients Associated With or Without White Matter Changes After Rivastigmine | Alzheimer's Disease | N/A | Completed | 300 | Open-label | rivastigmine patch |
| NCT01542866 A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD) | Age Related Macular Degeneration (AMD) | N/A | Completed | 160 | Open-label | — |
| NCT00203671 Mycophenolate Mofetil (MMF): A Long-Term Data Evaluation | Kidney Diseases | Completed | 651 | — | — | |
| NCT00149981 A Facilitated Access Program to Provide Everolimus (RAD) Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation | Organ Transplantation | NO_LONGER_AVAILABLE | — | — | everolimus (RAD) | |
| NCT04028245 A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma | Carcinoma, Renal Cell | Early P1 | Completed | 17 | Open-label | Spartalizumab, Canakinumab |
| NCT05787236 A Study of Moderate-to-severe Plaque Psoriasis Patients Response to Secukinumab Treatment in Real-world Setting | Moderate-to-severe Plaque Psoriasis | Completed | 79 | — | — | |
| NCT07168694 A Real-world Study About the Impact of Siponimod Treatment on Secondary Progressive Multiple Sclerosis Patients in Russia | Secondary Progressive Multiple Sclerosis | Completed | 606 | — | — | |
| NCT04498871 MAP to Provide Access to Nilotinib, for Patients With HES | Hypereosinophilic Syndrome (HES) | NO_LONGER_AVAILABLE | — | — | Nilotinib | |
| NCT05853445 A Prospective, Non-interventional Study of JAKAVI® (Ruxolitinib) Treatment in Patients With Polycythemia Vera | Polycythemia Vera | Completed | 467 | — | — | |
| NCT04614831 A Worldwide Survey on the Understanding of Psoriatic Disease Among Patients With Psoriasis and Psoriatic Arthritis | Plaque Psoriasis, Psoriatic Arthritis | Completed | 4,978 | — | — | |
| NCT02637219 Innate Immune Response in COPD | Pulmonary Disease, Chronic Obstructive, Immunity, Innate | Completed | 30 | — | — | |
| NCT02044237 Online Treatment of Trichotillomania | Trichotillomania, Alexithymia | N/A | Completed | 105 | RCT, Double-blind | — |
| NCT05112835 Brolucizumab Treatment Experience Study of Patients With nAMD in UK Routine Clinical Practice | Neovascular Age-related Macular Degeneration | Terminated | 302 | — | — | |
| NCT04645589 Evaluating the Safety of Myfortic (Mycophenolate Sodium) in Patients With Lupus Nephritis | Lupus Nephritis | Completed | 69 | — | Myfortic | |
| NCT06760624 Effectiveness of Ofatumumab in Real-world Practice | Multiple Sclerosis | Completed | 779 | — | — | |
| NCT03413722 Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Calcineurin Inhibitors (CNIs) to Everolimus | End Stage Renal Disease | Completed | 30 | — | Tacrolimus, Everolimus | |
| NCT03749681 Neuroendocrine Tumors of Old Patients in the West of France | Neuroendocrine Tumors | Unknown | 306 | — | — | |
| NCT05622929 Cluster Randomized Trial of a Digital Quality Improvement Intervention on LDLCholesterol Control | Cardiovascular Diseases, Atherosclerosis | N/A | Completed | 1,465 | RCT, Open-label | — |
| NCT05848219 Healthcare Resource Utilization and Costs in Metastatic Melanoma Patients Initiated Dabrafenib + Trametinib and Encorafenib + Binimetinib | Metastatic Melanoma | Terminated | 543 | — | — | |
| NCT00361595 Intervenous (IV) Zoledronic Acid After Forteo in Postmenopausal Women | Osteoporosis | N/A | Completed | 35 | Open-label | zoledronic acid |
| NCT00749320 Arterial Spin Labeling Blood Flow MRI for Evaluation of Response to Antiangiogenic and Targeted Therapies of Renal Cell Carcinoma (RCC) | Renal Cell Carcinoma | N/A | Completed | 32 | Open-label | — |
| NCT07450170 A Real-World Study of Omalizumab Treatment Patterns in Chronic Urticaria Patients in China | Chronic Urticaria | Completed | 3,485 | — | — | |
| NCT02232503 Prevalence of DIAbetic RETinopathy and Impact of Genetic Factors in the Development of Diabetic Retinopathy of Patients With Type 1 and 2 Diabetes Mellitus in SlovaKia | Diabetic Retinopathy, Diabetic Macular Edema | Completed | 4,011 | — | — | |
| NCT01733082 The Mycophenolate Pregnancy Registry | Heart Transplantation, Kidney Transplantation, Liver Transplantation, Autoimmune Diseases | Completed | 400 | — | — | |
| NCT05266469 Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in a Real-World Setting in the Gulf | Relapsing Multiple Sclerosis | Completed | 168 | — | — | |
| NCT02264665 OPALINE : A Study Of Morbidity And Mortality At 2 Years | Pancreatic Neuroendocrine Tumor, Well Differentiated and Progressive | Completed | 144 | — | sunitinib, everolimus, chemotherapies recommended in france | |
| NCT05334472 A Survey to Evaluate Early Experience From Patient and Care Partner on Injection and Device for KESIMPTA® Indicated for Multiple Sclerosis | Multiple Sclerosis | Completed | 105 | — | — | |
| NCT05388916 A Real-world Study to Assess Safety and Effectiveness of Secukinumab in Pediatric Plaque Psoriasis Patients in China | Moderate to Severe Chronic Plaque Psoriasis | Completed | 42 | — | — | |
| NCT02671006 Monitoring Chronic Urticaria Basophil Irritability by Cytometry | Urticaria | Completed | 60 | — | — | |
| NCT01220115 A 3-year, Prospective, Non-interventional, Multicenter Registry in Sickle Cell Disease (SCD) Patients | Sickle Cell Disease | Completed | 498 | — | — | |
| NCT04935411 Russian Registry of Patients With nAMD | Neovascular Age-Related Macular Degeneration | Terminated | 2,665 | — | — | |
| NCT01936519 Conversion to Everolimus From Calcineurin Inhibitor With Mycophenolic Acid: Impact on Long Term Renal Function in Liver Transplantation. | Immunosuppression, Renal Failure | N/A | Completed | 24 | RCT, Open-label | Arm A: Everolimus, Calcineurin Inhibitor |
| NCT01416311 Drug Use Investigation for REVOLADE (ITP) | Purpura, Thrombocytopaenic, Idiopathic | Completed | 5,797 | — | Eltrombopag | |
| NCT07376265 A Real-world Study to Compare the Effectiveness of Sacubitril/Valsartan Versus ACEi/ARB in HFrEF Patients | Heart Failure | Completed | 1,249 | — | — | |
| NCT00513487 Effects of Multiple Nasal Exposures to House Dust Mite Allergen on Nasal and Body Inflammation and Airway Sensitivity | Allergic Rhinitis | N/A | Completed | 18 | RCT, Open-label | Dust mite extract, Fluticasone, Methacholine |
| NCT07681258 A Study of Asciminib Safety and Efficacy in Young Adults With Chronic Myeloid Leukemia in the Gulf Region | Chronic Myeloid Leukemia | Not Yet Recruiting | 80 | — | — | |
| NCT01694589 A Pilot Study of a Hedgehog Pathway Inhibitor (LDE-225) in Surgically Resectable Pancreas Cancer | Resectable Pancreatic Cancer | Early P1 | Withdrawn | — | Open-label | LDE-225 |
| NCT05082415 Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (IRIS Study) | Age-related Macular Degeneration (AMD) | Completed | 9,456 | — | Brolucizumab | |
| NCT01163240 Epidemiological Study in Children and Adolescents With Chronic Hepatitis B | Liver Diseases, Hepatitis, Chronic | Completed | 1,640 | — | — | |
| NCT07072013 An Indirect Treatment Comparison of the Effectiveness of Ribociclib Combined With Non-steroidal Aromatase Inhibitors vs. Tamoxifen for the Adjuvant Treatment of Premenopausal Women With Hormon Receptor-positive, HER2-negative Early Breast Cancer | Breast Cancer | Completed | 1,937 | — | — | |
| NCT01376115 Drug Use Investigation for ARRANON G (Nelarabine) Injection 250mg | Cancer | Completed | 343 | — | Nelarabine | |
| NCT05426980 Artificial Intelligence in Predicting Progression in Multiple Sclerosis Study | Multiple Sclerosis, Multiple Sclerosis Lesion | Completed | 654 | — | — | |
| NCT00892398 Trabeculectomy With Mitomycin C Associated With Sub-conjunctival Injection of Ranibizumab | Glaucoma | N/A | Completed | 242 | RCT, Single-blind | ranibizumab |
| NCT07566988 A Real-world Study Comparing the Effectiveness of Ofatumumab and Ocrelizumab Treatment in Multiple Sclerosis Patients | Multiple Sclerosis | Completed | 2,604 | — | — | |
| NCT07465679 A Real-world Study of Clinical Treatment Guidelines for Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan | Heart Failure With Reduced Ejection Fraction | Completed | 2,508 | — | — | |
| NCT05376579 Impact of Mayzent on aSPMS Patients in a Long-term NIS in Italy | Active Secondary Progressive Multiple Sclerosis | Completed | 134 | — | — | |
| NCT04593927 Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients | Secondary Progressive Multiple Sclerosis (SPMS) | Completed | 451 | — | Mayzent | |
| NCT04741789 Managed Access Programs for INC280, Capmatinib | Non-Small Cell Lung Cancer | NO_LONGER_AVAILABLE | — | — | Capmatinib |